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ABSTRACT 
 Increasing muscle growth is beneficial to the meat animal industry and for 
biomedical research.  Altering myostatin function and administration of β-adrenergic 
agonists, such as clenbuterol, enhances muscle growth. However, it is unclear whether 
the mechanisms of these effects converge in a single pathway.  Previous work 
demonstrated that myostatin null mice (MKO) did respond to clenbuterol with increased 
body and muscle weights suggesting disparate mechanisms for each effect.  We 
examined gene expression profiles of these mice to identify downstream targets of 
myostatin null- and clenbuterol-induced skeletal muscle hypertrophy.  Microarray 
analysis was not successful at identifying gene expression differences between 
clenbuterol-treated and control mice.  Differences in gene expression between the MKO 
mice and wild type (WT) mice were observed including changes in genes related to 
amino acid and derivative metabolism - specifically creatine biosynthesis and 
metabolism, development, muscle contraction, transport, and Wnt receptor signaling.  
Real Time PCR (RT-PCR) was employed to validate genes associated with each of these 
processes in the tibialis anterior, gastrocnemius, and soleus muscles.  Additionally, 
creatine content and creatine kinase (CK) activity was directly measured in the tibialis 
anterior and gastrocnemius muscles.  Expression of nearly all genes investigated was 
consistent with microarray analysis, as was expression of myosin heavy chain isoforms.  
Furthermore, creatine and creatine kinase activity were increased in myostatin null mice 
compared with wild type mice.  Therefore this experiment confirms the role of myostatin 
as a negative regulator of muscle mass and also demonstrates some of the downstream 
effects of skeletal muscle hypertrophy associated with the myostatin null mutation. 
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CHAPTER 1 
REVIEW OF THE LITERATURE 
 Different hypertrophic mechanisms in muscle, while they may involve divergent 
upstream pathways, should ultimately converge on a common final set of processes.  
Identifying these processes, common genes, and transcripts would be beneficial to both 
animal agriculture and human biomedical research.  Alterations in myostatin 
functionality and administration of the β-adrenergic agonist clenbuterol have been well 
characterized for inducing skeletal muscle hypertrophy; however, the exact mechanisms 
behind these actions remain unclear.  This review will focus on muscle development, 
growth, and protein accretion with an emphasis on increasing muscle mass specifically 
by altering myostatin function or by clenbuterol administration.  It will also discuss 
microarray technology and quantitative real-time polymerase chain reaction (RT-PCR), 
two useful techniques for determining the physiological functions of myostatin and 
clenbuterol. 
Myogenesis 
 Embryonic formation of muscle fibers, or myogenesis, begins with mesenchymal 
precursor cells.  These cells first commit to the myogenic lineage by expressing muscle 
regulatory factors (MRFs) and proliferate, forming a pool of myoblasts.  The purpose of 
MRFs is to stop proliferation and induce differentiation.  Expression of the transcription 
factor, Pax3, promotes expression of these myogenic differentiation factors, including 
MyoD and Mrf5 (Williams and Ordahl, 1994). MyoD up-regulates p21, a cyclin 
dependent kinase inhibitor that prevents phosphorylation of the retinoblastoma protein 
(Rb) (Sherr and Roberts, 1999).  Phosphorylated Rb (pRb) inhibits cell cycle progression. 
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Myoblasts then withdraw from the cell cycle and are terminally differentiated.  Myoblasts 
fuse to form myotubes with centralized nuclei, and they accumulate myofibrils 
(contractile apparatus) and mature into functional muscle cells.  
Myostatin and myogenesis 
   Myostatin is a key regulator of skeletal muscle growth and development and is a 
member of the transforming growth factor-β (TGF-β) superfamily.  It negatively 
regulates skeletal muscle mass.  Myostatin possesses the characteristics of the TGF-β 
superfamily in that it is secreted as a latent complex.  Myostatin circulates in its latent 
form in both mouse and human serum (Hill et al., 2002).  In order for myostatin to be 
active, the inactive N-terminal signaling sequence, the propeptide, must first be cleaved 
from the C-terminal region.  A second proteolytic cleavage frees the active C-terminal 
fragment which allows receptor binding (McPherron, et al., 1997).   
 Myostatin function is highly conserved across vertebrate species (McPherron et 
al., 1997).  Mutations of the gene result in hyper-muscular phenotypes observed in cattle 
(Grobet et al., 1997; 1998; McPherron & Lee, 1997), humans (Schuelke et al., 2004), 
sheep (Clop et al., 2006) and dogs (Mosher et al., 2007).    Animals without functional 
myostatin exhibit primarily hyperplasia- an increase in the number of muscle fibers and 
to a lesser extent hypertrophy- an increase in the size of muscle fibers (McPherron & Lee, 
1997).   
 The inhibitory effect of myostatin on muscle growth begins during myogenesis.  
In vitro studies of C2C12 myoblasts treated with exogenous myostatin demonstrated 
significant up-regulation of p21 (Thomas et al., 2000) and reduced DNA synthesis 
(Taylor et al., 2001) suggesting myostatin inhibits myoblast proliferation. Myostatin also 
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inhibits differentiation.  Significant up-regulation of myostatin mRNA is observed during 
myogenic differentiation (Rios et al., 2002).  Myostatin inhibits MyoD expression 
(Langley et al., 2002), and down-regulates expression of other components of 
differentiation such as myogenin, downstream targets of myogenic differentiation factors, 
and creatine kinase (Ríos et al., 2001).  Conversely, double-muscled cattle fetuses exhibit 
increased expression of MyoD and increased differentiation in the absence of myostatin 
(Oldham et al., 2001).  Thus, functional myostatin inhibits both myoblast proliferation 
and differentiation, and the loss of myostatin function as in myostatin null mice results in 
the opposite effect: increased muscle hyperplasia (McPherron & Lee, 1997).   
Post-natal Muscle Growth  
Protein accretion 
 Because the number of skeletal muscle fibers is largely fixed at birth, postnatal 
muscle growth generally occurs via two mechanisms: by hypertrophy, the increase in size 
of muscle fibers, and by the accretion of material between cells.  Hypertrophy of muscle 
fibers is a result of the deposition of additional muscle protein and incorporation of more 
nuclei into the multi-nucleated muscle fiber.  Skeletal muscles grow in length via the 
addition of sarcomeres in response to stretch, and in width via the addition and/or 
splitting of myofibrils in response to work.  Both of these processes require increased 
protein accretion.  Protein accretion occurs when protein synthesized exceeds protein 
degraded; therefore protein accretion occurs as a result of increased synthesis and/or 
decreased degradation.  Protein synthesis occurs through signaling from various 
pathways including but not limited to insulin-like growth factor signaling, the PI3K-Akt-
mammalian target of rapamycin (mTOR) pathway, and through glycogen synthase kinase 
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3 β (GSK-3β) (reviewed by Glass, 2003).  Protein degradation in skeletal muscle is 
mediated by calcium-dependent activation of calpains, ATP-dependent ubiquitination, 
lysosomal proteases, and apoptosis (Glass, 2003).  
 In addition to its role in embryonic myogenesis, myostatin plays an important role 
in muscle growth throughout the life of an animal.  The myostatin protein is first detected 
in mouse embryos, and expression persists through adulthood (McPherron et al., 1997).  
Also, myostatin null mice retain their hyper-muscular phenotypes even with aging in 
contrast to normal mice (Wagner et al., 2005).  Postnatal expression of myostatin 
propeptide cDNA has also been shown to maintain high muscle growth (Yang et al., 
2001).  Recently, myostatin has been implicated as a negative regulator of the Akt/mTOR 
pathway (Amirouche et al., 2009).  This result has been confirmed with microarray 
experiments which identify components of the PI3K/Akt/GSK-3β as up-regulated in 
myostatin null mice (Chelh et al., 2009).  This introduces a new role for myostatin in the 
regulation of protein synthesis and confirms its important function in adult skeletal 
muscle.   
  Myostatin is also involved in muscle atrophy and increased protein degradation.  
For instance, patients with HIV express higher levels of myostatin in conditions of 
muscle wasting (Gonzalez-Cadavid et al., 1998).  Additionally, cachexia is induced in 
animals over-expressing myostatin (Zimmers et al., 2002). Conversely, administration of 
a myostatin antibody to dystrophic mice increases body and muscle weights while 
simultaneously reducing muscle degeneration and increasing levels of creatine kinase 
(Bogdanovich et al., 2002).  Myostatin has been shown to induce atrophy by up-
regulating genes involved in ubiquitin-mediated proteolysis (McFarlane et al., 2006).  
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 Another way to alter postnatal muscle protein accretion is use of β-adrenergic 
agonists (BAA) stimulating β-adrenoreceptors (B-AR), which are distributed differently 
but present in nearly all cell types.  Three subtypes of B-AR are present in skeletal 
muscle, β1, β2, and β3, but the β2 subtype is present in the greatest proportion ( Williams 
et al., 1984; Kim & Sainz, 1992) and may be most responsible for skeletal muscle 
hypertrophy (Hinkle et al., 2002).  Clenbuterol is a synthetic BAA that stimulates β2 B-
AR and increases muscle mass in numerous species such as mice, rats, cattle, chickens, 
pigs, and sheep (reviewed by Ricks et al., 1984).  The primary mechanism of action is to 
increase levels of cyclic AMP (cAMP) with subsequent activation of protein kinase A 
(reviewed by Mersmann, 1998).  Protein kinase A then activates several down-stream 
targets responsible for altering protein accretion. 
 One proposed downstream target of clenbuterol is insulin-like growth factors 
(IGF), which have been well characterized for their roles in protein synthesis and 
translation as well as myogenesis (reviewed by Jones & Clemmons, 1995).  
Administration of clenbuterol causes a transient increase of IGF-I in cells (Awede et al., 
2002) and of IGF-II in rat soleus (Sneddon, et al., 2001)  and masseter muscles   
(Matsumoto et al., 2006).  Clenbuterol, like other BAA, also activates the 
phosphoinositol 3-kinase (PI3K) - Akt signaling pathway (Schmidt et al., 2001; Kline et 
al., 2007) which is responsible for protein synthesis and proteolysis. Greater RNA 
accretion and total translational capacity is also observed in animals administered 
clenbuterol (Maltin et al., 1987), suggesting clenbuterol increases protein synthesis.      
 Clenbuterol also inhibits protein degradation as demonstrated in muscle wasting 
studies (Zeman et al., 1987; Zeman et al., 2000).  Lambs fed clenbuterol exhibit increased 
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concentrations of calpains and calpastatin (Higgins et al., 1988).  As further support of 
clenbuterol’s role in calcium-dependent proteolysis, Navegantes and colleagues 
(Navegantes et al., 2001) showed that clenbuterol inhibits Calcium-dependent proteolysis 
in rat muscles.  Clenbuterol has also been implicated in ATP-dependent proteolysis as 
rats treated with clenbuterol have reduced expression of ubiquitin mRNA (Costelli et al., 
1995). This effect was recently confirmed in a study that clenbuterol suppressed E3 
ubiquitin ligases (Kline et al., 2007).  The anabolic effects of clenbuterol are more 
prevalent in fast- twitch muscle fibers (Kim & Sainz, 1992), and it has been shown that 
clenbuterol inhibits ubiquitination in fast muscles more completely than in slow muscles 
(Yimlamai et al., 2005).   
Satellite cells 
 Though protein accretion occurs throughout muscle growth, the DNA: protein 
ratio of muscle cells is relatively constant, suggesting an increase in nuclei.  Because 
mature muscle cells are post-mitotic and unable to divide, they must acquire external 
DNA.  Unlike adult muscle cells, satellite cells retain their mitotic capacity and serve as 
myonuclei necessary for muscle growth, repair, and regeneration (Mauro, 1961).  As 
animals age, however, the satellite cell population decreases in absolute number and as a 
percentage of nuclei in skeletal muscle tissue (Snow, 1977).  The distribution of satellite 
cells also varies among muscle fiber types with slow muscle fibers having a greater 
proportion than fast muscle fibers (reviewed by Chen & Goldhamer, 2003). Satellite 
cells, in a similar manner to embryonic myoblasts, undergo multiple rounds of division 
prior to terminal differentiation and fusion to form multinucleated myofibers by 
mechanisms which are not clear (McKinnell et al., 2005).  Unlike myoblasts, however, 
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satellite cells maintain their ability to self-renew by generating identical daughter cells to 
restore the pool of quiescent satellite cells in a process called asymmetric division 
(Kuang et al., 2007). 
 Myostatin is expressed in satellite cells and regulates satellite cell quiescence and 
self-renewal (Cornelison et al., 2000).  Higher levels of myostatin have been observed in 
quiescent satellite cells and lower levels are observed when satellite cells are activated 
(McCroskery et al., 2005) .  Additionally, higher levels of myostatin are observed during 
immobilization, resulting in suppression of satellite cell activation (Carlson et al., 1999).  
In vitro studies revealed that myostatin null mice also exhibit greater proliferation and 
earlier differentiation of satellite cells (Wagner et al., 2005).  
   Clenbuterol perhaps plays a less direct role in satellite cell activation than 
myostatin, although it does induce hypertrophy. While clenbuterol directly affects the 
rate of protein synthesis- as shown by an up regulation in translational machinery 
(Spurlock et al., 2006), the direct effect on satellite cell activation has not been 
elucidated.   In whole muscle transplants, proliferation of satellite cells occurs sooner 
with clenbuterol treatment than without treatment (Roberts & McGeachie, 1992). 
Innervated and denervated muscles treated with clenbuterol exhibit increased activation 
of satellite cells; however, increases in mitosis are not observed (Maltin & Delday, 1992).  
Therefore, the effect of clenbuterol on satellite cell activity may be secondary to its’ 
effects on protein synthesis and degradation. 
Muscle Fiber Types 
 Following differentiation, myoblasts fuse to form myotubes with centralized 
nuclei.  Two waves of fusion occur.  The first wave gives rise to primary muscle fibers 
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which are generally slow and oxidative in mature animals.  A second wave of fusion 
gives rise to secondary muscle fibers.  These can become either fast or slow muscle fibers 
in mature animals.  These myotubes accumulate myofibrils, the contractile units of 
mature muscle, and the nuclei are pushed to the periphery of the cell.  Muscle fiber types 
are specialized and vary in their energy metabolism, contractile properties, and 
functionality (Edstrom & Kugelberg, 1968).  Slow twitch (red) fibers utilize oxidative 
metabolism and are fatigue-resistant.  Fast-twitch (white) fibers are more suited to use 
glycolytic metabolism but are not fatigue-resistant.   
 Muscle fibers can also be classified by myosin heavy chain (MHC) expression.  
The predominant protein in muscle fibers is myosin, consisting of four light chains and 
two heavy chains.  The major MHC isoforms determine the contractile properties of a 
fiber, and they are categorized differently based on their ATPase activity in the head 
region of the heavy chain (Brooke & Kaiser, 1970).  The major skeletal muscle MHC 
isoforms in mature muscle include MHCI, the slowest isoform, MHCIIb, the fastest, and 
MHCIIa and MHCIIx, which have intermediate contractibility.  Not all species exhibit 
the same distribution of fiber types and MHC isoforms.  Humans, for example, only 
exhibit three MHC isoforms (MHCI, MHCIIa, and MHCIIb) (Staron, 1997).      
 Lack of functional myostatin impacts fiber type in skeletal muscle.  Cattle with 
mutations in myostatin express more of fast, glycolytic isoforms (Wegner et al., 2000).  
Additionally, myostatin null mice exhibit more fast fibers in both slow and fast muscles 
as well as a greater proportion of fast MHC isoforms (Girgenrath, Song, & Whittemore, 
2005).  Microarray analysis also suggests an up-regulation in the faster, glycolytic MHC 
isoforms (Steelman et al., 2006). 
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 Administration of clenbuterol affects the contractile properties and metabolism of 
muscle fibers as well.  In rats, slow to fast muscle fiber type transition occurs in response 
to treatment with clenbuterol (Ricart-Firinga et al., 2000; Zeman et al., 1988).   In 
addition to altering muscle fiber type in rats, clenbuterol administration alters the MHC 
isoforms to favor the fast types and as a result induces metabolic adaptations to favor 
glycolytic metabolism (Rajab et al., 2000).    
 Increased expression of faster fiber types in hypertrophied muscle may result 
from differences in hypertrophic capacity of different fiber types. Faster fibers are larger 
in diameter and have a greater potential to undergo hypertrophy. Conversely, slower 
fibers, which are more dependent on the diffusion of oxygen for oxidative metabolism, 
are smaller in size and undergo less hypertrophy. Therefore, changes in fiber type 
distribution may reflect hypertrophic potential more than direct effects on expression of 
MHC proteins. This is not surprising as skeletal muscle hypertrophy preferentially occurs 
in the larger, type 2 muscle fibers in response to myostatin inactivation (Wegner et al., 
2000) and clenbuterol administration (Kim & Sainz, 1992).  
Objectives  
 Both myostatin and clenbuterol are powerful modulators of muscle growth.  The 
lack of functional myostatin and clenbuterol treatment are similar in that they both 
increase muscle mass and alter muscle fiber types. The same pathways have been 
implicated for both.  However, they are different because myostatin affects both prenatal 
development and postnatal growth whereas postnatal clenbuterol treatment only affects 
postnatal growth.  Therefore, the objective of the following studies was to identify similar 
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and disparate pathways leading to muscle hypertrophy in myostatin null and wild type 
mice treated with clenbuterol.  
Techniques for Identifying Pathways of Muscle Hypertrophy 
Microarray 
 Recent scientific advances, such as the sequencing of full genomes, have created a 
tremendous opportunity for researchers.  With these advances and other discoveries, tools 
for studying thousands of genes at once have become available.  One such example is 
DNA microarrays.  The concept of microarrays stems from basic concepts of gene 
expression.  While every cell in an organism possesses the same DNA, cells differ in the 
timing, intensity, and identity of genes they express.  Gene expression is measured in the 
amount of messenger RNA (mRNA) produced for a particular gene.  Techniques such as 
Northern blots or RT-PCR quantify expression of one gene at a time.  Microarrays allow 
examination of far more genes- up to the whole genome- at once and have been shown to 
elicit similar results as Northern blots (Taniguchi et al, 2001).  In addition to examining 
thousands of genes in parallel, microarrays compare gene expression profiles between 
two or more mRNA samples.  However, while microarrays provide insight into gene 
expression, protein expression, enzyme kinetics and other means must also be used to 
determine whether or not differences in transcription translate into physiological 
differences.  
  Two different types of microarrays exist: complementary DNA (cDNA) 
microarrays and oligonucleotide microarrays.  In cDNA microarrays, also known as 
spotted arrays, samples of cDNA, oligonucleotides, or other PCR products are 
synthesized prior to being affixed, or “spotted” on the microscope slide (Schena et al., 
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1995).  Conversely, oligonucleotide arrays are composed of short complementary 
sequences of specific oligonucleotides that are synthesized directly on the microscope 
slides (Lockhart et al., 1996).   Most microarrays utilize coated microscope slides with 
spots placed on the surface either through robotic spotting (Schena et al., 1995) or by 
using modified inkjet technology (Hughes et al., 2001).  Microarrays can contain an 
entire genome or contain only specific genes of interest to a particular research field.  For 
a genome-wide microarray, the genome must be sequenced and annotated.  On the array, 
every gene is represented by a “spot” and this spot contains multiple copies of a DNA 
sequence unique to that particular gene.   
 The procedure to perform a microarray analysis contains a series of basic steps 
including isolation of mRNA, production of labeled cDNA, hybridization of cDNA to the 
array and scanning to determine expression.  Total RNA, containing mRNA and other 
forms, is isolated from a tissue of interest.  Isolation of mRNA molecules away from 
other types of RNA is accomplished by binding the poly-adenine tail of the mRNA with 
buffers or columns. A copy of cDNA is produced from the mRNA by reverse 
transcription.  Using labeled nucleotides in the reverse transcriptase reaction making 
cDNA from mRNA results in a pool of labeled cDNA and facilitates comparing gene 
expression from two different samples. Cy3, fluorescent at 570 nm and greenish in color, 
and Cy5, fluorescent at 670 nm and reddish in color, are the two most commonly used 
dyes.  In the hybridization process, single-stranded cDNA binds to single-stranded DNA 
attached to the microarray slide.  
 After washing away unbound cDNA, microarrays are scanned by lasers to excite 
the fluorophores and are visualized.  More intense fluorescence corresponds to more 
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binding of cDNA at a particular spot and therefore, corresponds to increased expression 
of that particular gene in the tissue of interest.  Microarray scanners generally scan green 
(Cy3), red (Cy5) and yellow (the overlap of the two dyes), allowing for expression of 
genes to be compared between two samples.  Once the microarray has been scanned, the 
relative intensities of each fluorophore are used in ratio-based analysis to identify up-
regulated and down-regulated genes (Tang et al., 2007). 
 Various uses for microarray technology exist.  Because microarrays analyze 
thousands of genes simultaneously, gene expression differences can be determined 
between different tissues, time points, or treatments (Schulze & Downward, 2001). 
Microarrays are effective for studying small-sized samples and produce copious results 
quickly.  However, with all of these advantages also come drawbacks.  While 
microarrays generate large amounts of data, the data are simply lists of single genes 
which are up or down-regulated.  Additionally, microarray results must be validated with 
other applications.  Oftentimes validation may be a simple comparison of current results 
with past literature published on a subject (Chuaqui et al., 2002).  Results may also be 
validated by laboratory techniques such as Western blots to determine actual protein 
concentrations, or Northern blots and quantitative RT-PCR to determine mRNA levels 
(Lockhart & Winzeler, 2000).  Enzyme assays can also be utilized to determine if 
increased transcription results in increased enzyme activity.   
 In order to accommodate all of the data generated from microarray analysis, the 
Gene Ontology (GO) annotation was created.  Gene annotation clusters single genes into 
functional groups and pathways.  Three separate ontology categories are used: biological 
process, molecular function, and cellular component.  The biological process category 
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allows researchers to visualize all of the known processes in which a specific gene or 
group of genes is involved. The molecular function category describes what the gene or 
gene product does, but not necessarily where or when the event occurs.  The cellular 
component of GO illustrates where in the cell a gene product is active.  This system 
allows researchers to identify relationships between genes of interest as well as define the 
function of unknown genes (The Gene Ontology Consortium, 2000; 2001).  
Real-time quantitative PCR 
 Another way to examine genes of interest generated from a microarray is by RT-
PCR.  Unlike conventional PCR, RT-PCR collects data as the PCR process occurs, rather 
than at the endpoint of the reaction.  Researchers use RT-PCR because it quantifies 
differences in mRNA expression but uses smaller amounts of RNA than Northern 
blotting (reviewed by Bustin, 2002).  This is advantageous when experiments generate 
only small amounts of RNA such as in cell culture experiments or with samples from 
small animals.     
 The RT-PCR procedure uses either a one-step or two-step approach.  In the one-
step approach, reverse transcription and PCR are both performed in the same reaction 
tube.  In the two step approach, reverse transcription is performed prior to RT-PCR.  The 
one-step approach is quicker, less expensive, and requires less handling of samples 
reducing pipeting errors and possible contamination.  Gene specific primers are used 
during reverse transcription, however, limit quantification to one gene at a time.  The 
two-step approach uses random hexamer or oligonucleotide-dt primers to amplify all the 
mRNA present allowing for multiple genes to be investigated simultaneously (reviewed 
by Wong & Medrano, 2005). Also, two-step converts RNA into cDNA which is easier to 
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store and less susceptible to degradation than RNA.  Studies have shown that while the 
two approaches are similar in efficiency, the two-step approach may be slightly more 
sensitive and able to detect genes expressed in lower quantities (Peters, 2004).   
 During real time reactions using Applied Biosytems Taqman Primer/Probe 
system, release of a fluorescent molecule is measured (Heid et al., 1996).  Probes contain 
two fluorescent dyes; one which serves as a reporter at the 5’ end of the primer and one 
that serves as a quencher on the 3’end.  The close position of the quencher dye greatly 
reduces the fluorescence of the reporter dye (by fluorescence resonance energy transfer).  
When the probe anneals to a target sequence, it is cleaved by the 5’ exonuclease activity 
of Taq DNA Polymerase as the primer is extended (Holland et al., 1991).  Upon 
cleavage, the reporter dye emission is no longer transferred to the quencher dye, thus, 
fluorescence only occurs when new DNA is synthesized from the cDNA template.      
 The point at which the fluorescence crosses a threshold is known as the number of 
cycles to threshold (Ct).  Fewer cycles are needed to produce a detectable signal when a 
greater amount of target molecules are present.  Therefore a lower Ct value means more 
mRNA of a target sequence was present while a higher Ct values corresponds to less 
mRNA produced for a target sequence (Higuchi et al., 1993).  The Ct values are then 
standardized to the Ct of a housekeeper gene, a gene whose expression is stable among 
treatments.  This standardizes between samples for differences in starting cDNA 
concentrations.  Mathematical calculations allow for comparisons between groups or 
treatments in a fold-change manner.  A fold change equal to one indicates no differences 
in mRNA expression between treatments. Fold changes greater than one indicate up-
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regulation of mRNA, and fold changes less than one indicate down-regulation of specific 
mRNA.   
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CHAPTER 2 
 
GENE EXPRESSION PROFILING OF WILD TYPE AND MYOSTATIN NULL 
MICE TREATED WITH CLENBUTEROL 
 
 
Abstract 
 
 Increasing muscle growth is beneficial to the meat animal industry and for 
biomedical research.  Altering myostatin function and administration of β-adrenergic 
agonists, such as clenbuterol, enhances muscle growth. However, it is unclear whether 
the mechanisms of these effects converge in single pathway.  Previous work 
demonstrated that myostatin null mice (MKO) did respond to clenbuterol with increased 
body and muscle weights suggesting disparate mechanisms for each effect.  We 
examined gene expression profiles of these mice to identify downstream targets of 
myostatin null- and clenbuterol-induced skeletal muscle hypertrophy.  Microarray 
analysis was not successful at identifying gene expression differences between 
clenbuterol-treated and control mice.  Differences in gene expression between the MKO 
mice and wild type (WT) mice were observed including changes in genes related to 
amino acid and derivative metabolism, development, muscle contraction, transport, and 
Wnt receptor signaling.  These processes are linked to skeletal muscle hypertrophy and 
may provide interesting targets for future investigation.     
Introduction 
 
 Altering muscle growth has many applications for animal production and human 
health.  Skeletal muscle is important for locomotion and metabolism, and because muscle 
is converted to meat postmortem, it is highly targeted in animal research studies.  
Muscles grow by one of three mechanisms: by hyperplasia (increased cell number), by 
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hypertrophy (increased cell size), or by increasing the amount of material between cells.  
Muscle growth, therefore, can be manipulated by various methods.   
 One approach to increasing muscle growth is by altering functionality of 
myostatin, a negative regulator of muscle growth.  In cattle, natural mutations in the 
myostatin gene cause hyperplasia and increased muscle mass (Grobet et al., 1997; Grobet 
et al., 1998; Kambadur et al, 1997;  McPherron et al., 1997). The function of myostatin 
has been highly conserved across species with mutations also causing hyper-muscularity 
in dogs (Mosher et al., 2007), sheep (Clop et al., 2006), and humans (Schuelke et al., 
2004).  In addition to these natural mutations, transgenic mice lacking functional 
myostatin exhibit twice the amount of muscle as normal wild type mice as a result of 
hyperplasia and hypertrophy (McPherron et al., 1997).  These mice provide valuable 
insight into the study of muscle growth and development.   
 Mechanistically, myostatin inhibits myoblast cell proliferation by increasing the 
cell cycle inhibitor, p21, thus maintaining myoblasts in G1 phase of the cell cycle 
(Thomas et al., 2000, Taylor et al., 2001).  Myostatin also reduces myoblast 
differentiation by inhibiting MyoD expression and other components necessary for 
differentiation (Langley et al., 2002, Rios et al., 2002, Joulia et al., 2003).  In the absence 
of myostatin, myoblasts are more free to proliferate and differentiate, leading to prenatal 
hyperplasia (McPherron and Lee, 1997).  In the adult animal, myostatin regulates satellite 
cells (McCroskery et al., 2003) leading to increased satellite cell activity in animals 
lacking myostatin.  Additionally, animals without myostatin exhibit increased expression 
of fast myosin heavy chain (MHC) isoforms (Girgenrath et al., 2005).   
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 A second method for increasing muscle mass in animals involves the use of β-
adrenergic agonists (BAA).  Numerous species of animals administered BAA exhibit 
increased muscle mass including cattle, chickens, pigs, sheep, and mice (reviewed by 
Ricks, 1984).  One such BAA is clenbuterol which exerts its effect by increasing levels of 
the second messenger, cyclic adenosine monophosphate, activating protein kinase A.  
This activates several downstream components necessary for increased muscle growth.  
While the exact mechanism of clenbuterol action is still unclear, administration of this 
BAA increases protein synthesis (Emery et al, 1984; Claeys et al, 1989) and decreases 
protein degradation (Maclennan and Edwards, 1989; Anderson, 1991).  Clenbuterol also 
induces a fiber type transformation- favoring faster, more glycolytic fibers (Zeman et al., 
1988).  While animals administered clenbuterol share similar qualities to animals with 
myostatin null mutations, exact mechanisms of action for both remain unclear.   
 Previous work in our lab demonstrated that myostatin null mice (MKO) respond 
to clenbuterol with increased body and muscle weights (Dilger at al., 2009). In order to 
determine if this anabolic response resulted from similar or disparate mechanisms, gene 
expression profiles of myostatin null mice treated with clenbuterol were compared with 
wild type mice treated with clenbuterol.  This approach has previously been used in 
MKO mice (Steelman et al., 2006) and in wild type mice treated with clenbuterol 
(Spurlock et al., 2006), but our approach examined the effects of genotype and treatment 
simultaneously.     
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Materials and Methods 
Animals 
 Five-week old male mice were classified based on genotype (wild type (WT); 
n=32 or myostatin null (MKO); n=24) and were assigned to clenbuterol (20ppm in tap 
water; Sigma-Aldrich, St. Louis, MO, item # C5423) or control (tap water only) 
treatments.  All mice originated from an internal colony and were genotyped for the 
myostatin null mutation according to McPherron et al. (1997). Mice were housed 
individually under a 12/12h light/dark cycle and with free access to pelleted rodent chow 
(Teklad F6 rodent diet, Harlan, Indianapolis, IN) and water for two weeks.  At 7 weeks of 
age, mice were sacrificed by CO2 inhalation until cessation of breathing, followed by 
cervical dislocation.  Proximate composition of carcasses and individual muscle weights 
were used to confirm the effect of the transgene and the effect of clenbuterol 
administration. Results from these mice have been described elsewhere (Dilger et al., 
2009) and are displayed in Table 2.1.  The tibialis anterior (TA) muscles from four mice 
of each genotype and treatment were randomly selected for microarray (n=16).    
RNA isolation 
 Total RNA was isolated from muscle using the Trizol method (Invitrogen).  
Tissues were disrupted in Trizol with a TissueLyser (Qiagen, Valencia, CA).  Isolations 
were carried out according to the manufacturers’ directions.  Isolated RNA was 
quantified by spectrophotometry using a Nanodrop spectrophotometer (Nanodrop, 
Wilmington, DE).  Prior to microarray, RNA quality was determined using a 2100 
Bioanalyzer (Agilent, Palo Alto, CA). 
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 Microarray procedure 
 Mouse Exonic Evidence Based Oligonucleotide (MEEBO) Array (Invitrogen) 
contains 38,467 70-mer 5’ amino-modified oligonucleotide probes representing almost 
25,000 genes.  The MEEBO array includes: 35,302 probes targeting mouse genes, 97 
negative control probes, 1,152 positive control probes, and 1,916 doped control probes.  
All MEEBO slides were printed on Corning UltraGaps slides using a GeneMachines 
Omnigrid 100 microarray printer in the University of Illinois Functional Genomics 
Laboratory.   
 Total RNA from each TA sample was labeled using the Agilent Two Color 
QuickAmp Labeling Kit (Santa Clara, CA) according to the manufacturer’s protocol.  In 
short, 1 µg of each sample was reverse transcribed using a poly-dt promoter primer to 
create double stranded cDNA.  Antisense cRNA was then generated in vitro using T7 
RNA polymerase which simultaneously amplifies the target sample and incorporates 
cyanine 3 (Cy3)-cytidine triphosphate (CTP) or cyanine 5 (Cy5)-CTP.  To avoid dye 
bias, the experiments were performed using a loop design with dye swap of Cy3 and Cy5 
(Figure 2.1).  Samples were cleaned using a Qiagen RNAeasy column (Valencia, CA) 
and total synthesis and label incorporation was checked on a NanoDrop 
spectrophotometer.  Labeled probe was fragmented and suspended in Agilent 
hybridization buffer.  Slides were prehybridized with buffer containing: 20% Formamide, 
5X Denhardts, 6X SSC, 0.1% SDS, 25µg/ml tRNA and hybridized using a Biomicro 
Maui Mixer hybridization chamber.  Following wash, slides were scanned on an Axon 
4000B and image analysis carried out using the Axon GenePix Pro 6.1 Image Analysis 
software. 
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Statistical analysis 
 Microarray analysis was performed by a Functional Genomics Bioinformatics 
Specialist in the W.M. Keck Center for Comparative and Functional Genomics at the 
University of Illinois.  Quality control assessment, data pre-processing, and statistical 
analysis were performed using the limma (Smyth et al., 2005) package from the 
Bioconductor project (Gentleman et al, 2004). Spots that were manually flagged as “bad” 
due to dust specks, scratches, etc. were removed. Background correction was not done 
because the background was low and even on all the arrays. Within-array normalization 
for the red and green channels was performed using loess (averaging ratios from dye-
swapped hybridizations) on each print-tip group, and between-array normalization on the 
M values (logଶ
Rୣୢ
G୰ୣୣ୬
ሻ was done using the scale method (Smyth and Speed, 2003).  
 A mixed linear model equivalent to a 2x2 factorial ANOVA (genotype by 
clenbuterol treatment) was fit on the M-values, and an empirical Bayes correction was 
employed to improve power and decrease false positives when sample sizes are small 
(Smyth et al., 2004). Contrasts were pulled from the model to test for the main effects 
(genotype and clenbuterol treatment), the interaction, and four pair-wise comparisons 
between various genotype x treatment groups. To correct for multiple hypothesis testing 
within each contrast, the raw P-values were adjusted using the False Discovery Rate 
(FDR) method (Benjamini and Hochberg, 1995).  The effect of clenbuterol treatment was 
not significant and was therefore not included in subsequent analysis. 
 Gene Ontology Tree Machine (GOTM), a web-based tool for data analysis and 
data visualization for sets of genes, was used to categorize genes identified as genes of 
interest to this study (bioinfo.vanderbilt.edu/gotm/).  Using a background list of genes 
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supplied by the user, GOTM estimates the expected number of genes to fall into each GO 
category by chance.  A given GO category is considered enriched (P<0.01), or 
significant, when the observed number of altered genes exceeds the number of expected 
genes for that GO category (Zhang et al, 2004). 
Results and Discussion 
 
Microarray  
 
 Microarray analysis identified 14,604 genes as expressed across all arrays, and 
only these genes were included in subsequent analysis.  The effect of clenbuterol on gene 
expression was minimal, as were the results of specific contrasts of clenbuterol treated 
and untreated mice.  Only four genes were differentially expressed based on the main 
effect of clenbuterol treatment (FDR-adjusted P≤0.10).  Also, only two genes were 
differentially expressed in clenbuterol-treated WT mice compared with control WT mice 
and in clenbuterol-treated MKO mice compared with control MKO mice (FDR-adjusted 
P≤0.10).  Furthermore, there was no significant interaction of genotype and treatment 
with regards to gene expression as detected by microarray. 
 While a physiological response to clenbuterol was apparent in treated mice 
(increased body and muscle weights shown in Table 2.1), no significant changes in gene 
expression were detected.  These results conflict with previous microarray data 
(Spurlock, 2006) which identified many differentially expressed genes when comparing 
mice treated with clenbuterol to control mice. However, between our study and the one 
previously published, there were differences in animal age, clenbuterol dosage and mode 
of administration, and the microarray platform which all could have contributed to 
differences between the two studies.  Also, treatment duration was longer in our study 
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which may have diluted some of the gene expression effects.  Furthermore, it is possible 
that changes in gene expression were too small for the assay to detect due to our limited 
sample size. 
The effect of genotype on gene expression, however, was apparent from both the 
specific contrast of MKO and WT control mice and the overall main effect of genotype.  
The comparison of MKO control mice with WT control mice identified 277 genes as 
significant (FDR-adjusted P-value ≤ 0.10); however, with a more stringent FDR adjusted 
P-value ≤ 0.05, only 6 genes were differentially expressed.  Examining the main effect of 
genotype, 2428, 854, and 130 genes were differentially expressed based on FDR-adjusted 
P-values 0.20, 0.10, and 0.05 respectively.  These results were similar to previous 
microarray (Steelman et al, 2006) comparing MKO and WT mice at five weeks of age.   
Gene ontology annotation 
 Gene Ontology Tree Machine (GOTM) was used to annotate genes deemed 
significant.  Gene set for ontology analysis was extended to include all genes with an 
FDR of 20% or lower to yield a more complete overview; however, genes were limited to 
those with fold changes ≥1.4 (expressing 40% more of a particular mRNA) or ≤ 0.6 
(expressing only 60% of a particular mRNA).  Overall, this set included 255 genes (listed 
in Appendix).  This set was analyzed by GOTM and referenced against the 14,604 genes 
expressed on the arrays, labeled as background.  The distribution of genes in the 
significant gene list in each Gene Ontology (GO) category was compared to those genes 
in the background gene list.  After the two gene lists were compared, a significance of 
enrichment (P-value) was assigned to each GO category indicating if selected genes were 
overrepresented in some categories.   
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  Gene Ontology (GO) spans three domains; biological process, molecular function, 
and cellular component.  We focused on the biological process domain.  Analysis by 
GOTM suggested 30 GO categories of enriched gene expression within this domain 
which were divided into five main groups as shown by Figure 2.1.  All of these biological 
processes contain genes related to skeletal muscle growth and metabolism. All genes 
from each of the five main categories are shown in Table 2.2-2.5.   
 The first group consisted of genes related to amino acid and derivative 
metabolism (Table 2.2).  A total of nine genes from this group were altered in MKO 
mice. This pathway culminated at creatine biosynthesis and metabolism, and therefore 
creatine biosynthesis was included as a sub-category from this main category. Both 
enzymes responsible for creatine synthesis, guanidinoacetate methyltransferase (Gamt) 
and glycine amidinotransferase (L-arginine: glycine amidinotransferase) (Gatm) were up-
regulated in MKO mice compared with WT mice.  Therefore, the lack of myostatin may 
increase creatine synthesis or creatine content in MKO mice.   
 The second biological process category consisted of genes related to development 
(Table 2.3).  Expression of 41 genes from this group was altered in MKO mice.  The role 
of myostatin in development is to limit muscle growth by inhibiting proliferation of 
myoblasts (Thomas et al., 2000; Taylor et al., 2001) and differentiation of myoblasts 
(Langley et al., 2002; Rios et al., 2002; Joulia et al., 2003).  Thus, myostatin mutants 
exhibit hyperplasia (McPherron and Lee, 1997) and the lack of myostatin function in 
MKO mice would be expected to alter elements of muscle development.  Two such genes 
were up-regulated in the MKO mice compared with the WT mice: homeobox A11 
(Hoxa11) and sine oculis-related homeobox 2 homolog (Drosophilia) (Six2).  Previous 
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research demonstrated that Hoxa11 inhibits MyoD expression in developing limb buds 
(Yamamoto and Kuroiwa, 2003).  Therefore this gene may act similarly to myostatin and 
decrease proliferation and inhibit differentiation.  In a similar manner, Six2 limits 
expression of myogenin (Spitz et al., 1998) and MyoD (Giordani et al., 2007).  The 
upregulation of these genes may be an adaptation to substitute for the lack of myostatin 
function. 
 Another notable gene in this category was the transcription factor forkhead box 
D3 (Foxd3).  Embryonic studies with Foxd3 have shown that it is essential for 
maintaining pluripotent embryonic stem cells (Hanna et al, 2002), and its’ increased 
expression may be related to the expected increase in satellite cells in MKO mice.  SRY-
box containing gene (Sox6), was also up-regulated in MKO mice compared with WT 
mice.  Animals lacking a functional SOX6 protein express predominantly slow MHC 
isoforms (Hagiwara et al., 2007).  Therefore, SOX6 may be related to increasing or 
maintaining fast fibers, which are increased in MKO mice.       
 The third group of enriched genes consisted of genes related to muscle contraction 
(Table 2.4).  Expression of nine genes from this group was altered in MKO mice 
including slow myosin heavy chain isoforms (MHC), Myhc1 and Myhc2 corresponding to 
MHCI and MHCIIa, respectively.  Microarray analysis suggested that expression of 
slower MHC isoforms (I and IIa) was decreased in MKO mice compared with WT mice 
(FDR-adjusted P≤0.20), while expression of the fastest MHC isoforms (IIb) was slightly 
higher (fold change=1.42) in MKO mice compared with WT mice (FDR-adjusted 
P≤0.20).  Expression of MHCIIx appeared lower in MKO mice compared with WT mice 
(FC=0.57, data not shown), however the difference was not significant (FDR adjusted 
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P>0.20).  Steelman et al. (2006) found similar down-regulation of slow MHC isoforms 
with a microarray comparing MKO and WT mice at five weeks of age.  Overall, these 
data would suggest that MKO mice display a faster MHC profile than WT Mice. 
Alterations in MHC isoforms have previously been illustrated in myostatin mutant 
animals (Girgenrath et al, 2005) similar to this result.   
 The fourth group consisted of genes related to transport (Table 2.5).  A total of 40 
genes from this group were altered in MKO mice. For example, genes involved in fatty 
acid transport in skeletal muscle, such as fatty acid binding protein 3 (Fabp3), Cd36 
antigen (Cd36), and very low density lipoprotein receptor (Vldlr), were down-regulated. 
Reduced expression of these genes may result in reduced fatty acid transport into muscle 
of MKO mice. This result may be related to the aforementioned fiber type change in 
MKO mice.  Because myostatin mutant animals have an increased proportion of fast, 
glycolytic muscle fibers, less fatty acid oxidation may be occurring in these muscles.  
Therefore, the uptake of fatty acids into the tissue may be decreased, and the elements of 
fatty acid transport may also be down-regulated. 
 Other transport genes linked to muscle metabolism were also altered in the MKO 
mice compared with the WT mice including major urinary proteins (MUPs) which were 
significantly upregulated in MKO mice compared with WT mice.  Recently, 
administration of recombinant major urinary protein 1 has been shown to enhance insulin 
signaling via the Akt signaling cascade in skeletal muscle (Hui et al., 2009), however the 
exact mechanism of mechanisms by which MUPs exert this effect are uncertain.  
Incorporation of the myostatin null mutation has been shown to reduce insulin resistance 
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and improve fasting blood glucose in obese lines of mice (McPherron 2002). It is 
possible that increased expression of MUP would explain this phenomenon.            
 The fifth group consisted of genes related to Wnt receptor signaling. Four genes 
from this group were altered in MKO mice. However, the biological process of Wnt 
receptor signaling was excluded from further analysis because its significance has 
previously been described (Steelman et al., 2006) who showed that components of the 
Wnt/Calcium pathway were up-regulated in MKO mice, resulting in increased satellite 
cell proliferation.  
Conclusions 
  This experiment corroborates with previous microarrays which also demonstrated  
alteration of genes related to Wnt receptor signaling and muscle contraction (Steelman et 
al., 2006).  Furthermore, several  biological processes identified by GO including 
development and creatine synthesis have been previously linked to myostatin or skeletal 
muscle hypertrophy.         
 Other results from the microarray were more surprising. For instance, though a 
physiological response was observed in clenbuterol-treated MKO and WT mice, there 
were few changes in gene expression. The original aim of the study was to look for 
similarities between the two modes of hypertrophy, this, however, was not accomplished. 
Thus, we cannot conclude from these results whether the modes of action of myostatin 
null mutation and clenbuterol treatment overlap or are disparate. The additive nature of 
each effect physiologically would suggest the two mechanisms are separate. To further 
investigate this matter, it may be beneficial to treat animals for a shorter time period 
similar to other microarray studies. Also, Spurlock and colleagues (2006) concluded that 
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the increase in protein synthesis associated with clenbuterol administration may more 
likely be a result of up-regulation of translational initiators, rather than a sustained up-
regulation of gene expression at the transcriptional level.  Thus, minimal differences in 
gene expression would be observed. In the future, we could also re-examine the gene lists 
more closely and perhaps set less stringent standards for significance.  
 In summary, this transcriptomic investigation demonstrates that lack of functional 
myostatin affects the biological processes of development, amino acid and derivative 
synthesis and metabolism, muscle contraction, transport, and Wnt receptor signaling.  
Together, these results demonstrate the global effects of altering myostatin activity in 
mice.  While alterations in these biological processes are not surprising, the 
characterization of many of the genes involved in these processes, particularly skeletal 
muscle development, is still underway.  Further exploration of individual genes and 
groups of these genes will provide insight into the mechanisms behind skeletal muscle 
hypertrophy.  Therefore, each of these categories should be examined individually to 
define specific roles of each process and of individual genes within a process.  This may 
help us to better understand the exact mechanisms behind myostatin inhibition of skeletal 
muscle growth. 
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 Table 2.1. Effects of genotype (G) and clenbuterol treatment (T) and their interaction (GxT) on body weight, carcass weight and 
content and tibialis anterior weight of wild type and myostatin null mice1 
 
  Wild Type  Myostatin Null  P-value 
  Control Clenbuterol  Control Clenbuterol  G  T GxT 
Body weight (g) 22.4 ± 0.53 23.8 ± 0.53 25.9 ± 0.61 27.2 ± 0.59 <0.01 0.02 0.92 
Empty carcass weight (g) 8.8 ± 0.29 10 ± 0.29 12.9 ± 0.34 14.1 ± 0.32 <0.01 <0.01   0.99 
Empty carcass fat (%) 7.1 ± 0.30 5.4 ± 0.30 4.7 ± 0.38 3.8 ± 0.33 <0.01 <0.01   0.24 
Empty carcass protein (%) 20.9 ± 0.22 21.7 ± 0.22 21.5 ± 0.28 22.1 ± 0.24 0.04 0.01   0.69 
Tibalis anterior muscle 
(%) 2 0.20 ± 0.015 0.23 ± 0.015 0.37± 0.016 0.40 ± 0.016 < 0.01   0.03 0.94 
 
1 Mice were allowed free access to tap water with 20 ppm clenbuterol (Clenbuterol) or without (Control). Values are 
lsmeans ± S.E.M. 
2Expressed as a percentage of body weight.  
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 Figure 2.1.  Loop Design utilized for two-color microarray.  Samples were hybridized in 
duplicate using dye swap of Cy3 and Cy5 as demonstrated by the different arrows. 
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Figure 2.2.  Main groups of Biological Processes identified by Gene Ontology Tree Machine analysis. Gene Ontology Tree 
Machine estimates the expected number of genes to fall into each GO category by chance.  A given GO category is considered 
enriched (P<0.01), or significant, when the observed number of altered genes exceeds the number of expected genes for that 
GO category  
 
 
0
5
10
15
20
25
30
35
40
45
Amino Acid & 
Derivative 
Metabolism
Creatine 
Biosynthesis & 
Metabolism
Development Muscle 
Contraction
Transport Wnt Receptor 
Signaling
N
u
m
b
e
r
 
o
f
 
G
e
n
e
s
Observed Expected
P=0.00054
P=0.0042
P=4.29x10-6
P=0.00013
43 
P=2.14x10-5
P=0.0029
 
 
 
 
  Table 2.2.  Genes involved in amino acid and derivative metabolism and creatine 
biosynthesis and metabolism differentially expressed between myostatin null and wild 
type mice. 
Amino Acid and Derivative Metabolism
Symbol Gene Name Fold Change1 
Amd1 S-adenosylmethionine decarboxylase 1 0.52 
Coror2a coronin, actin binding protein 2A 1.52 
Ddc dopa decarboxylase 1.46 
F12a1 coagulation factor XIII, A1 subunit 1.46 
Gamt guanidinoacetate methyltransferase 1.52 
Gatm glycine amidinotransferase (L-arginine:glycine amidinotransferase) 1.66 
Nr4a2 nuclear receptor subfamily 4, group A, member 2 1.41 
Tph1 tryptophan hydroxylase 1 1.68 
Ttr transthyretin 2.14 
 
Creatine Biosynthesis and Metabolism
Symbol Gene Name Fold Change1 
Gamt guanidinoacetate methyltransferase 1.52 
Gatm glycine amidinotransferase (L-arginine:glycine amidinotransferase) 1.66 
1Fold change compares myostatin null to wild type. 
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 Table 2.3 Genes involved in development differentially expressed between 
myostatin null and wild type mice.  
 
Development 
Symbol Gene Name Fold Change 
Actc1 actin, alpha, cardiac 2.57 
Adamst4 a disintegrin-like and metallopeptidase with thrombospondin type 1 motif, 4 1.42 
Amd1 S-adenosylmethionine decarboxylase 1 0.52 
Ank1 ankyrin 1, erythroid 1.57 
Atp6v01a1 ATPase, H+ transporting, lysosomal V0 subunit A1 1.51 
Bin1 bridging integrator 1 1.48 
Cd28 CD28 antigen 2.22 
Chd7 chromodomain helicase DNA binding protein 7 1.41 
Csrp3 cysteine and glycine-rich protein 3 0.39 
Ctnnbpip1 catenin beta interacting protein 1 1.51 
Cxc4 chemokine (C-X-C motif) ligand 4 1.51 
Dach2 dachshund 2 (Drosophila) 0.58 
Dkk3 dickkopf homolog 3 (Xenopus laevis) 1.78 
Emp1 epithelial membrane protein 1 1.63 
Esrrg estrogen-related receptor gamma 0.57 
Foxd3 forkhead box D3 1.52 
Gab3 growth factor receptor bound protein 2-associated protein 3 1.43 
Gamt guanidinoacetate methyltransferase 1.52 
Hoxa11 homeo box A11 1.58 
Igf2 insulin-like growth factor 2 2.44 
Il15  interleukin 15 0.61 
Jun  Jun oncogene 1.40 
Kazald1 Kazal-type serine peptidase inhibitor domain 1 1.65 
Lgals3 lectin, galactose binding, soluble 3 1.98 
Lrp6 low density lipoprotein receptor-related protein 6 1.64 
Mafb v-maf musculoaponeurotic fibrosarcoma oncogene family, protein B  0.54 
Mb myoglobin 0.49 
Myh1 myosin, heavy polypeptide 1, skeletal muscle, adult 0.56 
Nfic nuclear factor I/C 1.47 
Nov nephroblastoma overexpressed gene 1.43 
Nr4a2 nuclear receptor subfamily 4, group A, member 2 1.41 
Nrtn neurturin 1.42 
Pdlim3 PDZ and LIM domain 3 1.46 
Pigt phosphatidylinositol glycan anchor biosynthesis, class T 1.45 
Prkg1 protein kinase, cGMP-dependent, type I 0.48 
Six2 sine oculis-related homeobox 2 homolog (Drosophilia) 1.42 
Sox6 SRY-box containing gene 6 1.54 
Spon2 spondin 2, extracellular matrix protein 1.99 
Trp63 transformation related protein 63 1.48 
Wnt4 wingless-related MMTV integration site 4 1.41 
1Fold change compares myostatin null to wild type. 
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 Table 2.4 Genes involved in muscle contraction differentially expressed between 
myostatin null and wild type mice.  
 
Muscle Contraction 
Symbol Gene Name Fold Change1 
Actc1 actin, alpha, cardiac 2.57 
Actn3 actinin alpha 3 1.68 
Atp2a1 ATPase, Ca++ transporting, cardiac muscle, fast twitch 1 1.49 
Mybph myosin binding protein H 2.9 
Myh1 myosin, heavy polypeptide 1, skeletal muscle, adult 0.56 
Myh3 myosin, heavy polypeptide 3, skeletal muscle, embryonic 0.59 
Myh4 myosin, heavy polypeptide 4, skeletal muscle  1.42 
Myh8 myosin, heavy polypeptide 8, skeletal muscle, perinatal 2.25 
Pde4b phosphodiesterase 4B, cAMP specific 1.42 
1Fold change compares myostatin null to wild type. 
 
Table 2.5 Genes involved in Wnt receptor signaling differentially expressed between 
myostatin null and wild type mice.  
Wnt Receptor Signaling 
Symbol Gene Name Fold Change1
Catnbip1 catenin beta interacting protein 1 1.51 
Dkk3 dickkopf homolog 3 (Xenopus laevis) 1.78 
Lrp6 low density lipoprotein receptor-related protein 6 1.64 
Wnt4 wingless-related MMTV integration site 4 1.41 
1Fold change compares myostatin null to wild type.  
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Table 2.6 Genes involved in transport differentially expressed between myostatin null 
and wild type mice.  
Transport 
Symbol Gene Name Fold Change1 
9530003J23Rik RIKEN cDNA 9530003J23 gene 0.56 
Abca ATP-binding cassette, sub-family A (ABC1), member 1 0.61 
Abra actin-binding Rho activating protein 1.43 
Alb1 albumin 1 4.07 
Ambp1 alpha 1 microglobulin/bikunin 1.53 
Ank1 ankyrin 1, erythroid 1.57 
Ap1m2 adaptor protein complex AP-1, mu 2 subunit 1.45 
Atp1b1 ATPase, Na+/K+ transporting, beta 1 polypeptide 0.40 
Atp2a1 ATPase, Ca++ transporting, cardiac muscle, fast twitch 1 1.49 
Atp6v0a1 ATPase, H+ transporting, lysosomal V0 subunit A1 1.51 
BC021785 cDNA sequence BC021785 1.51 
Bin1 bridging integrator 1 1.48 
C3 complement component 3 0.53 
Cd36 CD36 antigen 0.57 
Chrna1 cholinergic receptor, nicotinic, alpha polypeptide 1 (muscle) 1.55 
Col16a1 procollagen, type XVI, alpha 1 1.41 
Col1a1 procollagen, type I, alpha 1 1.67 
Emid2 EMI domain containing 2 1.41 
Fabp1 fatty acid binding protein 1, liver 2.33 
Fabp3 fatty acid binding protein 3, muscle and heart 0.34 
Fabp4 fatty acid binding protein 4, adipocyte 0.60 
Fndc5 fibronectin type III domain containing 5 0.60 
Fth1 ferritin heavy chain 1 1.42 
Fxyd6 FXYD domain-containing ion transport regulator 6 0.59 
Gatm glycine amidinotransferase (L-arginine:glycine amidinotransferase) 1.66 
Kcnc4 potassium voltage gated channel, Shaw-related subfamily, member 4 1.42 
Kif17 kinesin family member 17 1.46 
Ktn1 kinectin 1 2.00 
Lrp6 low density lipoprotein receptor-related protein 6 1.64 
Mb myoglobin 0.49 
Mup1 major urinary protein 1 2.09 
Mup2 major urinary protein 2 2.43 
Mup3 major urinary protein 3 1.76 
Slc16a6 solute carrier family 16 (monocarboxylic acid transporters), member 3 1.54 
Sypl2 synaptophysin-like 2 1.55 
Tom1l2 target of myb1-like 2 (chicken) 1.45 
Ttr transthyretin 2.14 
Tubb6 tubulin, beta 6 1.43 
Vldlr very low density lipoprotein receptor 0.57 
1Fold change compares myostatin null to wild type. 
 
CHAPTER 3 
CHANGES IN GENE EXPRESSION, CREATINE CONTENT AND ENZYME 
ACTIVITY IN MYOSTATIN NULL MICE AND WILD TYPE MICE 
 
Abstract 
 Inhibiting myostatin function in animals has provided valuable insight into 
mechanisms underlying skeletal muscle growth and hypertrophy.  However, many of the 
downstream effects of myostatin remain unclear.  Previous microarray analysis by our lab 
suggested that the myostatin null mutation affects numerous biological processes 
including development, transport, muscle contraction, and amino acid and derivative 
metabolism- specifically creatine biosynthesis and metabolism.  Real Time PCR (RT-
PCR) was employed to validate genes associated with each of these processes in the 
tibialis anterior (TA), gastrocnemius (GAS), and soleus muscles.  Additionally, creatine 
content and creatine kinase (CK) activity were directly measured in the TA and GAS 
muscles.  Expression of nearly all genes investigated was consistent with microarray 
analysis, as was expression of myosin heavy chain isoforms.  Furthermore, creatine and 
CK activity were increased in myostatin null mice compared with wild type mice.  
Therefore this experiment confirms the role of myostatin as a negative regulator of 
muscle mass and also demonstrates some of the downstream effects of skeletal muscle 
hypertrophy associated with the myostatin null mutation.    
 
Introduction  
 Analysis by microarray suggested differences in gene expression between 
myostatin null (MKO) and wild type (WT) particular to several biological process 
categories including development, transport, muscle contraction, and amino acid and 
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derivative metabolism-specifically creatine biosynthesis and metabolism. To confirm 
these results, genes were selected for validation by Real-Time PCR (Table 3.1). The first 
three genes, Meg3, Igf2, and Il15, are related to muscle development and growth.  
Meg3/Gtl2 is a non-coding RNA whose function is unclear (Miyoshi et al., 2000; Zhou et 
al., 2007); however, expression of the gene is elevated in sheep with the callipyge 
mutation (Charlier et al., 2001), suggesting a role for this gene in protein turnover and 
skeletal muscle hypertrophy.  The role of Igf2, another maternally imprinted gene, has 
been highlighted in various growth studies.  Gene manipulation studies in mice illustrated 
that Igf2 modulates muscle mass during fetal development (DeChiara et al., 1990; 
Leighton et al., 1995).  Additionally, IGF2 partners with IGF1 to stimulate myoblast 
differentiation (Florini et al., 1991; Pirskanen et al., 2000) and plays a role in satellite cell 
proliferation (Haugk et al., 1995). Increased mRNA expression of Igf2 is common in 
double-muscled cattle breeds as well (Gerrard and Grant, 1994; Listrat et al., 1999).  
Interleukin 15 (IL15) is a muscle-specific cytokine that has recently been implicated in 
skeletal muscle hypertrophy (Quinn et al., 2009) and in modulation of fast myosin heavy 
chain isoforms (Quinn et al., 1995).    
 The next four genes, cluster of differentiation (Cd36), fatty acid binding protein 3 
(Fabp3), very-low density lipoprotein receptor (Vldlr), and lipoprotein lipase (Lpl) are 
involved in fatty acid transport.  Overexpression of Cd36, also known as fatty acid 
translocase, enhances fatty acid oxidation in skeletal muscle (Ibrahimi et al., 1999).  
Conversely, Cd36 null animals cannot effectively oxidize fatty acids (Coburn et al., 
2000).  Like Cd36, Fapb3 is involved in fatty acid transport and muscle energy 
metabolism (Binas and Erol, 2007) and genetic lack of Fabp3 impairs fatty acid uptake 
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and oxidation (Binas et al., 1999).  Very low density lipoprotein receptor function is not 
well characterized although mice lacking Vldlr exhibit significant reductions in fat mass 
(Frykman, Brown, Yamamoto, Goldstein, and Herz, 1995).  Lipoprotein lipase binds to 
Vldlr (Takahashi et al., 1995) and deficiencies in LPL reduce fat mass-much like Vldlr 
null mice (Weinstock et al., 1997) suggesting a synergistic relationship. 
 Additionally, microarray analysis and previous work indicated MKO mice 
displayed a change in fiber type composition (Girgenrath et al., 2005).  These changes in 
fiber type composition are mainly the result of decreased expression of slow myosin 
heavy chain (MHC) isoforms (Steelman, Recknor, Nettleton, and Reecy, 2006).  Because 
myostatin is preferentially expressed in fast muscle fibers, myostatin mutant animals 
exhibit primarily fast-twitch fiber hypertrophy (Carlson et al., 1999; Deveaux et al., 
2003). 
Finally, microarray analysis suggested altered creatine metabolism in MKO mice. 
Creatine is found in cells with high and fluctuating energy demand such as skeletal 
muscle and heart (Wyss and Kaddurah-Daouk, 2000), and is synthesized from arginine, 
glycine, and methionine in two enzyme-catalyzed reactions.  The first reaction involves 
the transfer of an amidino group from arginine to the amino group of glycine.  This 
reaction is catalyzed by L-arginine:glycine amidinotransferase (Gatm), and the resulting 
products are guanidinoacetate (GAA) and ornithine.  In the second reaction, GAA is 
methylated by S-adenosylmethionine (SAM) to produce S-adenosylhomocysteine (SAH) 
and creatine.  This reaction is catalyzed by guanidinoacetate methyltransferase (Gamt).  
Microarray analysis indicated increased expression of both Gamt and Gatm.  
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 Therefore, the objective of this experiment was to confirm the results of the 
microarray in a separate replicate of MKO and WT mice. We were interested in 
extending the result of the microarray which focused on the tibialis anterior muscle to 
other muscles. Also, we investigated creatine content and activity of creatine kinase 
directly. 
 
Materials and Methods 
Animals 
   Seven-week old male MKO mice (n=8) from an internal colony and seven-week 
old male WT mice (n=8) (C57BL/6J, Jackson Laboratories, Ben Harbor, ME) were group 
housed (4 animals per cage) under a 12/12h light/dark cycle and with free access to 
pelleted rodent chow (Teklad F6 rodent diet, Harlan, Indianapolis, IN) and water.  Mice 
were sacrificed by CO2 inhalation until cessation of breathing, followed by cervical 
dislocation. The following muscles were dissected and weighed from these mice: 
gastrocnemius (GAS), tibialis anterior (TA), triceps brachii (TB), biceps femoris (BF), 
and soleus (SOL).  Muscle samples were immediately frozen at -80°C and GAS, TA, and 
SOL muscles were used for RNA extraction and Real-Time PCR (RT-PCR).  Because of 
their small size, SOL muscles from 3 animals were pooled together resulting in only 2 
samples of SOL muscle for each genotype.  
RNA isolation 
 Total RNA was isolated from individual TA (n=16) and GAS (n=16) muscles and 
pooled SOL samples (n=4) using the Trizol method (Invitrogen).  Tissues were disrupted 
in Trizol with a TissueLyser (Qiagen, Valencia, CA).  Isolations were carried out 
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according to the manufacturers’ directions.  Isolated RNA was quantified by 
spectrophotometry using a Nanodrop spectrophotometer (Nanodrop, Wilmington, DE).   
Real-time PCR 
 For two-step RT-PCR, cDNA was synthesized from 2µl RNA (0.5µg/µl) using 
the Quantitect Reverse Transcription Kit (Qiagen, Valencia, CA).  cDNA was diluted 
1:100 following primer probe validation experiments as recommended by the 
manufacturer.  Real-Time PCR reactions (1µl 1:100 diluted cDNA per reaction) were 
performed in triplicate on a 7900HT thermal cycler/fluorescence detector (Applied 
Biosystems, Foster City, CA) using Taqman Universal Master Mix and gene specific 
primers (Table 3.1)  Relative quantification was performed to determine changes in 
expression of the selected genes in the myostatin null mice compared with the wild type 
mice.  Fold changes in gene expression were determined using the ΔΔCt method (Livak 
and Schmittgen, 2001) with samples normalized to the level of glyceraldehyde-3-
phosphate dehydrogenase (Gapdh). Suitability of Gapdh as a housekeeper was confirmed 
by determining that expression of this gene did not differ between genotypes.    
Creatine assay 
 Using manufacturers’ recommendations, TA and GAS muscles (30 mg) were 
homogenized in 1mL of creatine assay buffer containing 0.1% Triton X-100.  
Homogenates were pelleted by centrifugation (15000 x g for 10 minutes at room 
temperature) and the supernatant was filtered with a 10K spin filter (BioVision, 
Mountainview, CA product # 1997) to remove any heavy proteins or enzymes that could 
interfere with the assay. Samples were diluted 1:100, and creatine content was measured 
using the Creatine Assay Kit (BioVision, Mountainview, CA).  This assay utilizes the 
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enzymatic conversion of creatine to sarcosine which reacts with an oxidative enzyme to 
produce peroxide as a byproduct.  The peroxide reacts with a probe to produce a colored 
product detected by spectroscopy at 570 nm after one hour of incubation at 37° C.   
Creatine kinase assay 
 Using manufacturers’ recommendations, TA and GAS muscles (30 mg) were 
homogenized in 1mL of 80mM MES (2-(N-morpholino) ethanesulfonic acid) Buffer 
pH=6 in a Tissuelyser (Qiagen, Valencia, CA). Homogenates were diluted 1:200 and 
creatine kinase activity was measured using the EnzyChromTM Creatine Kinase Assay Kit 
(BioAssay Systems, Hayward, CA). This assay uses an enzyme-coupled reaction in 
which creatine phosphate and ADP are converted to creatine and ATP by CK.  The 
generated ATP from this reaction is used by hexokinase to phosphorylate glucose, 
resulting in the formation of glucose-6-phosphate (G6P).  In the presence of G6P 
dehydrogenase, G6P is oxidized and NADPH is produced.  The amount of NADPH 
produced is proportionate to the CK activity in the sample and is detected by 
spectroscopy at 340 nm after 10 min and 40 min of incubation at 37° C.   
Statistical analysis 
 All data were analyzed with the MIXED procedure of SAS (Version 9.1; SAS 
Inst., Inc., Cary, NC, USA).  The LSMEANS (least square means) statement was used for 
means and standard error calculations.  For RT-PCR and body weight data, model 
statement included the main effect of genotype.  For creatine and CK activity, the initial 
model statement included the effect of genotype, muscle, and the genotype x muscle 
interaction.  The muscle x genotype interaction was not significant (P >0.05) so it was 
removed from the model.   
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Results and Discussion 
Body and muscle weights 
 
    Body weight was increased (P<0.01) in MKO mice compared with WT mice 
(Table 3.2).   Weights of the triceps brachii, GAS, and TA muscles were increased 
(P<0.01) in MKO mice compared with WT mice with the most pronounced differences 
between genotypes observed in the triceps brachii and GAS (P<0.0001).  Muscle weight 
was increased 24% to 77% in MKO compared with WT mice.  Although numerically 
increased, the biceps femoris of MKO was not statistically different from the WT.  Soleus 
muscle weight, however, from MKO mice (0.013g) and WT mice (0.012g) was not 
different. 
Expression of select genes from microarray analysis 
   In TA muscle, Meg3, Igf2, and Gamt, were up-regulated (P<0.05) in MKO mice 
compared with WT mice (Figure 3.1A).  Conversely, Lpl was down-regulated (P<0.05) 
in MKO mice compared with WT mice (Figure 3.1A). Expression of Fapb3 and Cd36 
was also lower in MKO mice compared to WT mice, but not significant statistically.  The 
expression of Vldlr was not consistent with the microarray data presented in Chapter 2 as 
it was found to be significantly down-regulated by microarray analysis yet up-regulated 
in RT-PCR analysis (P<0.05).  Additionally, expression of Il15 was not altered in TA 
muscles.   
 In the GAS muscle, Meg3, Igf2, and Gamt were all up-regulated (P<0.05) in the 
MKO mice compared with the WT mice. Also, Cd36, Fabp3, and Lpl were down-
regulated (P<0.05) in MKO mice compared with WT mice (Figure 3.1B). In contrast to 
the result of TA muscle, Vldlr expression was lower (P=0.06) in the GAS muscle of 
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MKO mice compared with WT mice and therefore, moves in concert with other fat-
transport genes. These results are consistent with previous microarray data from TA 
muscle with the exception of Il15. It was unchanged in the GAS muscle of MKO mice 
compared with WT mice.  
  In the SOL muscle, none of the genes examined were found to be statistically 
different between the MKO mice and the WT mice (Figure 3.1C) perhaps due to the very 
small sample size for this muscle. Though no genes were statistically different, numerical 
changes in gene expression observed between MKO mice and WT mice in SOL muscle 
were similar to the GAS and TA.  This included increased Meg3, Igf2, and Gamt 
expression in MKO mice compared with WT and reduced expression of Lpl, Vldlr, and 
Fabp3.  
 Genes from all muscles showed fairly consistent changes in gene expression- 
aside from Vldlr and Il15.  Microarray analysis showed decreased gene expression of 
Vldlr in TA muscles of MKO mice compared with WT mice.  RT-PCR analysis of the 
TA, however, showed increased gene expression of Vldlr.  While Weinstock and 
colleagues (1997) previously suggested a synergistic relationship between Lpl and Vldlr, 
Vldlr has been shown to function independently of Lpl (Tiebel et al., 1999) and this could 
explain the discrepancy among the related genes.  Microarray analysis also showed 
decreased expression of Il15 in TA muscle, but RT-PCR analysis showed no significant 
changes in Il-15 expression between MKO and WT mice in TA and GAS muscle.  This 
could be a result of the cutoff we used for gene annotation purposes (FDR-adjusted p-
value ≤0.20) in our microarray. Setting significance at 20% means that we accept that 
20% of the genes from the list are expected to be false positives, but this was an 
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acceptable trade off for us to obtain more true positives.  This in combination with the 
borderline fold change of Il15 (FC=0.61) increases the likelihood that it was not 
significantly affected by genotype.   
  Real-time PCR- muscle fiber types 
   Genes for (MHC) isoforms Myh1, Myh2, Myh7, and Myh4 correspond to 
proteins MHCI, MHCIIa, MHCIIx, and MHCIIb, respectively and will subsequently be 
referred to as such.  In the TA muscle, MHCI, MHCIIx and MHC IIa were reduced       
(P <0.06) in MKO mice compared with WT mice (Figure 3.2A). Expression of MHCI, 
the slowest isoform, was reduced 50% in MKO mice compared with WT mice while 
expression of MHCIIa and MHCIIx were further reduced.  Expression of both 
intermediate isoforms (MHCIIa  and MHCIIx)  in MKO mice was less than 10% of  WT  
expression (P< 0.06). Expression of MHCIIb, however, was not altered in MKO mice.  
These results are consistent with our previous microarray analysis which showed 
significant down-regulation of MHCI and MHCIIa.    In the GAS muscle, only 
expression of MHCIIa was significantly lower (P<0.01) in MKO mice compared with 
WT mice (Figure 3.2B).  There were no significant differences in MHCI, MHCIIx, or 
MHCIIb expression between the two genotypes; however, expression of MHCI and 
MHC2x was numerically lower in MKO mice (P≥0.15).   
 Overall, the TA and GAS both exhibited reduced gene expression of slow MHC 
isoforms, rather than an increase in the fastest isoform, MHCIIb.  These results, overall, 
would suggest a shift away from slow isoforms of MHC expression consistent with 
previous reports (Girgenrath et al., 2005).  Steelman and colleagues (2006) also reported 
similar findings in the pectoralis muscle of MKO mice.   Double muscled cattle exhibit 
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primarily fast-twitch fiber hypertrophy (Wegner et al., 2000; Deveaux et al., 2003).  
Muscle weight data (Table 3.2) suggested greater hypertrophy in GAS muscles 
suggesting it possessed more fast fibers. Therefore we expected to see a more pronounced 
change in MHC isoforms expression in GAS than in TA muscle, but the opposite was 
true. Therefore, it is unclear which of the two muscles would be considered faster 
phenotype in MKO mice. To clarify this point, individual muscle fiber size as it relates to 
muscle fiber type could be examined.  Furthermore expression and activity of glycolytic 
enzymes and oxidative enzymes may provide a clearer picture of fiber type shifts in 
MKO mice.  
 In SOL muscle, no significant differences in MHC gene expression were observed 
between the MKO mice and the WT mice (Figure 3.2C).  Expression of both MHCI and 
MHCIIx was slightly higher in the SOL muscle of MKO mice compared with WT mice 
but did not reach a level of statistical significance.  In the future a larger number of SOL 
samples should be used.  However, given the lack of increase in SOL weight in MKO 
mice, it is possible that the slow, oxidative soleus is less responsive to the muscle fiber 
type switching observed in fast muscles.  This is consistent with previous studies which 
show that myostatin is preferentially expressed in fast muscle fibers, and myostatin null 
mice exhibit primarily fast-twitch fiber hypertrophy (Carlson et al., 1999)  similar to 
double-muscled cattle (Wegner et al., 2000; Deveaux et al., 2003).                       
Creatine and creatine kinase 
Results from microarray and RT-PCR analyses would suggest differences in 
creatine content between MKO mice and WT mice.  Past studies have used creatine and 
creatinine in the blood as a marker for double-muscled cattle (Hanset R. and Michaux C., 
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1982), further supporting this assumption.  Expression of Gamt was increased in MKO 
mice compared with WT mice (P<0.05), but expression data reveals little regarding 
enzyme activity. Thus, creatine content, the end product of the reaction catalyzed by 
GAMT, was measured directly in TA and GAS muscles. Creatine content of MKO mice 
was increased (P<0.001) nearly 40% compared with WT mice (Table 3.3). The TA had 
slightly higher creatine content than the GAS muscle (P=0.102), but there was no 
interaction of muscle and genotype for creatine content.  During intense contraction, fast 
muscle fibers exhibit large ATP depletions while slow muscle fibers do not (Meyer and 
Terjung, 1979), therefore slow muscles have a lower requirement for immediate 
replenishment of ATP.  Therefore, the increased creatine content in TA compared with 
GAS muscle may be secondary to fiber type composition. Similarly, increased creatine 
content in MKO mice may also be related to the shift in fiber type.  This could be 
confirmed by measuring creatine content of individual fast muscle fibers compared with 
individual slow fibers.              
Research demonstrates that creatine synthesis occurs primarily in the liver and 
kidneys (Sandberg et al., 1953).  However, the contribution of other tissues, including 
skeletal muscle and brain, to creatine synthesis is uncertain.  It is generally assumed that 
a creatine transporter is responsible for uptake of creatine into tissues such as skeletal 
muscle, cardiac muscle, and brain; however, recent studies have suggested that the brain 
is capable of producing its own creatine because Gatm and Gamt are expressed in this 
tissue (Braissant et al., 2001). Confirmed expression of Gatm and Gamt in skeletal 
muscle in this study and others (Braissant et al., 2005) would suggest that skeletal muscle 
also synthesizes creatine.  However, it would be interesting to also measure creatine 
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uptake and expression of the creatine transporter in MKO mice to confirm that increased 
creatine synthesis is responsible for increased creatine content in these animals.   
 Creatine binds to phosphate, forming phosphocreatine (PCr).  Sudden energy 
demands result in the de-phosphorylation of ATP to ADP.  Phosphocreatine donates its 
phosphate to ADP to renew the ATP lost and produce energy.  The enzyme responsible 
for the phosphorylation of creatine is CK.  Increased CK activity in MKO mice compared 
with WT mice (P=0.10) was observed in this study.  Creatine kinase activity of myostatin 
null mice was 919.96 U/gram of muscle compared with 855.25 U/gram of muscle in wild 
type mice (Table 3.3).  While not statistically significant (P=0.145), CK activity of TA 
was 916.23 U/gram while CK activity of GAS was 858.98U/ gram of muscle tissue.  
Consistent with the functional demand placed on the muscle, increased CK activity was 
expected in faster muscles such as the TA.  Fast muscles have an increased demand for 
ATP replenishment (Meyer and Terjung, 1979) and possess more total creatine and 
phosphocreatine than slow muscles (Brault and Terjung, 2003; Murphy et al., 2001).   
 
Conclusions 
  The main objective of this experiment was to confirm the results of previous 
microarray analysis which suggested that lack of functional myostatin altered numerous 
biological processes in MKO mice compared with WT mice.  We previously described 
those biological processes and individual genes involved in each process.  The results of 
that experiment were limited to the fast TA muscle, however, so we investigated the same 
genes in GAS, and SOL muscles.  Genes from all muscles showed fairly consistent 
changes in gene expression- aside from Vldlr and Il-15.   
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 Typical of myostatin mutant animals, body and muscle weights were increased in 
MKO mice compared with WT mice, with the exception of the SOL muscle.  No 
significant differences in gene expression were observed in the MKO mice compared 
with the WT mice but this may be partially attributed to the limited sample size of SOL 
muscle.  Similar changes in gene expression were observed in this muscle compared with 
the other two muscles despite the lack of physiologically response in SOL muscle weight. 
Conversely, the SOL muscle was unresponsive to changes in gene expression of MHC 
isoforms typically associated with the myostatin null mutation. This suggests slow 
muscle gene expression may be altered with the lack of myostatin function though the 
effect on muscle weigh is limited.    
 Microarray analysis also indicated increased expression of the two enzymes 
responsible for creatine biosynthesis, Gatm and Gamt.  Increased expression of Gamt was 
further confirmed by RT-PCR, suggesting that skeletal muscles are capable of 
synthesizing their own creatine, and may not be fully dependent on external sources.  
Creatine content and CK activity was measured directly and was found to be increased in 
MKO compared with WT mice.  We hypothesize that increased fast fiber content of 
MKO mice results in higher creatine content and CK activity compared with WT mice; a 
direct result of the fiber type composition and the energy demands of the fast fibers. 
Future studies should examine the uptake of creatine into skeletal muscles of MKO mice 
versus WT mice to validate these assumptions.     
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 Table 3.1. Primers used for RT-PCR. Fold Changes (FC) and P-values are from previous 
microarray analysis. 
Symbol Product 
Genebank  
Accession 
TaqMan 
 Assay ID FC Pvalue 
Igf2 insulin-like growth factor 2 NM_010514 Mm00439565_g1 2.44 0.04 
Meg3 
 
Gtl2, imprinted maternally 
expressed untranslated mRNA NM_144513 Mm00522599_m1 2.96 0.11 
Gamt 
 
guanidinoacetate methyltransferase NM_010255 Mm00487473_m1 1.52 0.07 
Cd36 
 
CD36 antigen NM_007643 Mm01135198_m1 0.58 0.07 
Vldlr 
 
very low density lipoprotein 
receptor NM_013703 Mm00443281_m1 0.57 0.07 
Il15 
 
interleukin 15 NM_008357 Mm00434210_m1 0.61 0.09 
Lpl 
 
lipoprotein lipase NM_008509 Mm00434764_m1 0.54 0.04 
Fabp3 
 
fatty acid binding protein 3, muscle 
and heart NM_010174 Mm02342494_m1 0.43 0.07 
Myh1 
 
myosin, heavy polypeptide 1, 
skeletal muscle, adult XM_354615 Mm01332489_m1 0.56 0.16 
 
Myh2 
myosin, heavy polypeptide 
2, skeletal muscle, adult NM_144961 Mm00454982_m1 0.18 0.10 
Myh4 
 
myosin, heavy polypeptide 4, 
skeletal muscle XM_126119 Mm01332541_m1 1.42 0.16 
Myh7 
 
myosin, heavy polypeptide 7, 
cardiac muscle, beta NM_080728 Mm00600555_m1 0.57 0.40 
Gapdh 
 
glyceraldehyde-3-phosphate 
dehydrogenase NM_008084 Mm99999915_g1 - - 
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Table 3.2.  Effect of genotype on body weight and individual muscle weights in the 
myostatin null (MKO) and wild type (WT) mice.   
  
Genotype 
       WT MKO S.E.M. P-value 
Number of mice 8 8 
Body Weight (g) 21.28 23.87 0.605 0.009 
Muscles 
  Biceps Femoris (g) 0.30 0.32 0.012 0.160 
  Triceps Brachii (g) 0.16 0.29 0.092 <.0001  
  Gastrocnemius (g) 0.24 0.34 0.127 <.0001  
  Tibialis Anterior (g)  0.13 0.17 0.007 0.003 
  Soleus (g)  0.012  0.013 0.001 0.537 
Values are lsmeans ± S.E.M. 
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Table 3.3. Effects of genotype and muscle on creatine content and creatine kinase activity 
in wild type and myostatin null mice. 
 
  
Creatine Content  
(mg/g) 
Creatine Kinase      
(U/g) 
Number of mice 6 6 
Genotype 
   Wild Type 2.91 855.25 
   Myostatin Null 3.99 919.96 
S.E.M.   0.148   26.75 
P-value   <0.0001     0.75 
Muscle 
   Tibialis Anterior 3.48 916.23 
   Gastrocnemius 3.41 858.98 
S.E.M.  0.148   26.75 
P-value  0.102    0.15 
 Values are lsmeans ± S.E.M. 
U=Unit Creatine Kinase where 1 Unit of CK will transfer 1 µmole of phosphate 
from phosphocreatine to ADP per minute at pH 6.0. 
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Figure 3.1.  Fold change in gene expression of the Tibialis Anterior (A), Gastrocnemius 
(B), and Soleus (C) muscles in myostatin null (MKO) and wild type (WT) mice.  Bars 
represent least square means ± standard error and * indicates MKO differs from WT (P < 
0.05).     
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Figure 3.2.  Fold change in gene expression of myosin heavy chain isoforms in the 
Tibialis Anterior, Gastrocnemius, and Soleus muscles of myostatin null(MKO) and wild 
type (WT) mice.  Mean fold change represents least square means ± standard error and * 
indicates MKO differs from WT (P < 0.05). 
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APPENDIX 
 
List of genes for Gene Ontology Tree Machine Annotation 
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Symbol Product FC FDR-adj.P.Value 
Myh8 myosin, heavy polypeptide 8, skeletal muscle, perinatal  2.25 0.003 
1110001A05Rik 
Mus musculus RIKEN cDNA 1110001A05 gene 
(1110001A05Rik), mRNA. 1.80 0.012 
Esrrg estrogen-related receptor gamma 0.57 0.012 
Prkg1 protein kinase, cGMP-dependent, type I  0.48 0.013 
Mgst1 microsomal glutathione S-transferase 1 0.54 0.013 
9630033F20Rik RIKEN cDNA 9630033F20 gene 0.55 0.015 
Myo10 myosin X 1.53 0.028 
Wdfy1 WD repeat and FYVE domain containing 1 3.34 0.039 
2310042L06Rik RIKEN cDNA 2310042L06 gene 1.50 0.039 
Mybph myosin binding protein H 2.90 0.043 
Cd28 CD28 antigen 2.22 0.043 
1110059G02Rik RIKEN cDNA 1110059G02 gene 1.78 0.043 
Itgb1 
Mus musculus integrin beta 1 (fibronectin receptor beta) 
(Itgb1), mRNA. 1.59 0.043 
Triobp 
Mus musculus TRIO and F-actin binding protein 
(Triobp), mRNA. 1.56 0.043 
Coro2a coronin, actin binding protein 2A  1.52 0.043 
Htr6 5-hydroxytryptamine (serotonin) receptor 6 1.48 0.043 
2310061J03Rik 
Mus musculus RIKEN cDNA 2310061J03 gene 
(2310061J03Rik), mRNA. 1.45 0.043 
9430063L05Rik RIKEN cDNA 9430063L05 gene 1.44 0.043 
Gdf3 growth differentiation factor 3 1.42 0.043 
Foxo3 Mus musculus forkhead box O3 (Foxo3), mRNA. 1.41 0.043 
Dach2 dachshund 2 (Drosophila) 0.58 0.043 
A530026G17 hypothetical protein A530026G17 0.56 0.043 
Lpl lipoprotein lipase 0.54 0.043 
Ldh2 lactate dehydrogenase 2, B chain  0.44 0.043 
LOC210321 epididymal protein Av381126 0.35 0.043 
Triobp TRIO and F-actin binding protein 1.47 0.043 
4833412C05Rik RIKEN cDNA 4833412C05 gene 2.55 0.043 
Cfl2 Mus musculus cofilin 2, muscle (Cfl2), mRNA. 1.53 0.043 
Nr5a2 
Mus musculus nuclear receptor subfamily 5, group A, 
member 2 (Nr5a2), mRNA. 1.49 0.043 
Kif17 kinesin family member 17 1.46 0.043 
Tom1l2 target of myb1-like 2 (chicken) 1.45 0.043 
2210008N01Rik RIKEN cDNA 2210008N01 gene 1.43 0.043 
9130213B05Rik RIKEN cDNA 9130213B05 gene 1.41 0.043 
Gpd1 glycerol-3-phosphate dehydrogenase 1 (soluble) 1.40 0.043 
Bhlhb3 basic helix-loop-helix domain containing, class B3  1.40 0.043 
Fxyd6 FXYD domain-containing ion transport regulator 6 0.59 0.043 
Plac9 placenta specific 9 0.58 0.043 
Lpl lipoprotein lipase 0.54 0.043 
Prkg1 protein kinase, cGMP-dependent, type I  0.52 0.043 
Igf2 insulin-like growth factor 2 2.44 0.044 
Dusp13 dual specificity phosphatase 13 1.56 0.044 
C530050O22Rik RIKEN cDNA C530050O22 gene 1.51 0.044 
2410005H09Rik RIKEN cDNA 2410005H09 gene 1.48 0.044 
Renbp renin binding protein 1.47 0.044 
Pvrl3 
Mus musculus poliovirus receptor-related 3 (Pvrl3), 
mRNA. 1.41 0.044 
Dlk1 delta-like 1 homolog (Drosophila) 1.41 0.044 
Jun Jun oncogene 1.40 0.044 
Ppp1r14c protein phosphatase 1, regulatory (inhibitor) subunit 14c  1.39 0.044 
Lrrn1 leucine rich repeat protein 1, neuronal  0.52 0.044 
Grb14 
Mus musculus growth factor receptor bound protein 14 
(Grb14), mRNA. 0.48 0.044 
C130068O12Rik RIKEN cDNA C130068O12 gene 1.43 0.046 
r171.1 Rat cytomegalovirus Maastricht, complete genome. 1.41 0.046 
Actc1 actin, alpha, cardiac  1.91 0.047 
1110030K22Rik RIKEN cDNA 1110030K22 gene 0.54 0.047 
Cbfa2t1h 
Mus musculus CBFA2T1 identified gene homolog 
(human) (Cbfa2t1h), mRNA. 1.40 0.047 
9530064J02 hypothetical protein 9530064J02 2.45 0.048 
Hist2h3c2 histone 2, H3c2  1.43 0.048 
C3 complement component 3 0.53 0.049 
B230312C02Rik RIKEN cDNA B230312C02 gene 1.95 0.049 
Phc2 
Mus musculus polyhomeotic-like 2 (Drosophila), 
mRNA (cDNA clone IMAGE:5321987), complete cds. 1.50 0.051 
Fbp2 fructose bisphosphatase 2 1.73 0.051 
Ddr1 
Mus musculus discoidin domain receptor family, 
member 1 (Ddr1), mRNA. 1.44 0.051 
Gdf8 growth differentiation factor 8 0.11 0.051 
4832428D23Rik RIKEN cDNA 4832428D23 gene 2.25 0.052 
6430548M08Rik MKIAA0513 protein (Fragment). 1.81 0.055 
0610041G09Rik RIKEN cDNA 0610041G09 gene 1.67 0.055 
1110012O05Rik RIKEN cDNA 1110012O05 gene 1.66 0.055 
8030402F09Rik RIKEN cDNA 8030402F09 gene 1.65 0.055 
6430548M08Rik RIKEN cDNA 6430548M08 gene 1.60 0.055 
Banp Btg3 associated nuclear protein 1.52 0.055 
Csda 
Mus musculus cold shock domain protein A (Csda), 
mRNA. 1.52 0.055 
Catnbip1 catenin beta interacting protein 1 1.51 0.055 
Mus musculus 13 days embryo head cDNA, RIKEN 
full-length enriched library, clone:3110005M20 
product:serine/arginine-rich protein specific kinase 2, 
full insert sequence. 1.50 0.055 
Mkl1 MKL (megakaryoblastic leukemia)/myocardin-like 1 1.48 0.055 
F730017E11Rik RIKEN cDNA F730017E11 gene 1.48 0.055 
1700003N22Rik RIKEN cDNA 1700003N22 gene 1.47 0.055 
Tenc1 
Mus musculus tensin like C1 domain-containing 
phosphatase, mRNA (cDNA clone MGC:47266 
IMAGE:4188303), complete cds. 1.43 0.055 
Fth1 ferritin heavy chain 1 1.42 0.055 
Abca1 ATP-binding cassette, sub-family A (ABC1), member 1  0.61 0.055 
1100001H23Rik RIKEN cDNA 1100001H23 gene 0.53 0.055 
Temt thioether S-methyltransferase 0.44 0.055 
Bdh 3-hydroxybutyrate dehydrogenase (heart, mitochondrial) 0.31 0.055 
Sfrs2 splicing factor, arginine/serine-rich 2 (SC-35)  1.55 0.057 
Ctss cathepsin S 1.51 0.057 
Nrtn neurturin 1.42 0.057 
Bdh 3-hydroxybutyrate dehydrogenase (heart, mitochondrial) 0.36 0.057 
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Tceal5 transcription elongation factor A (SII)-like 5 1.83 0.057 
Hn1 hematological and neurological expressed sequence 1 1.42 0.057 
Pdlim7 PDZ and LIM domain 7 1.53 0.058 
Wnt4 wingless-related MMTV integration site 4 1.41 0.058 
Gab3 
growth factor receptor bound protein 2-associated 
protein 3 1.43 0.061 
2310057H16Rik RIKEN cDNA 2310057H16 gene 1.43 0.061 
5230400C17Rik RIKEN cDNA 5230400C17 gene 0.59 0.061 
9130213B05Rik RIKEN cDNA 9130213B05 gene 1.57 0.063 
Wnt2b 
Mus musculus wingless related MMTV integration site 
2b (Wnt2b), mRNA. 1.52 0.063 
Dab2ip disabled homolog 2 (Drosophila) interacting protein 1.47 0.063 
Ent2 
Mus musculus equilibrative nitrobenzylthioinosine-
insensitive nucleoside transporter ENT2 (Ent2) mRNA, 
complete cds. 1.47 0.066 
Vldlr very low density lipoprotein receptor 0.57 0.066 
Cd36 CD36 antigen 0.58 0.066 
Sox6 SRY-box containing gene 6 1.54 0.068 
Trp63 transformation related protein 63 1.48 0.068 
Gamt guanidinoacetate methyltransferase 1.52 0.068 
Pdlim3 PDZ and LIM domain 3 1.46 0.068 
Xlkd1 extra cellular link domain-containing 1 1.42 0.069 
Ank1 ankyrin 1, erythroid  1.57 0.069 
Mtvr2 mammary tumor virus receptor 2 1.43 0.069 
B230106I24Rik RIKEN cDNA B230106I24 gene 0.60 0.069 
Fabp3 fatty acid binding protein 3, muscle and heart  0.43 0.069 
D5Ertd593e DNA segment, Chr 5, ERATO Doi 593, expressed  1.56 0.070 
Dctn2 dynactin 2 1.52 0.070 
Dctn1 dynactin 1 1.44 0.070 
Actc1 actin, alpha, cardiac  2.57 0.071 
Peg3 paternally expressed 3 1.54 0.071 
Epb4.9 
Mus musculus erythrocyte protein band 4.9 (Epb4.9), 
mRNA. 1.50 0.071 
Actb Mus musculus actin, beta, cytoplasmic (Actb), mRNA. 1.77 0.071 
Mg29 mitsugumin 29 1.55 0.071 
BC021785 cDNA sequence BC021785 1.51 0.071 
Ap1m2 adaptor protein complex AP-1, mu 2 subunit  1.45 0.071 
Gadd45a growth arrest and DNA-damage-inducible 45 alpha 1.43 0.071 
Fndc5 fibronectin type III domain containing 5 0.60 0.071 
Pdhb pyruvate dehydrogenase (lipoamide) beta 0.60 0.071 
B130052G07Rik RIKEN cDNA B130052G07 gene 1.59 0.071 
Slc16a3 
solute carrier family 16 (monocarboxylic acid 
transporters), member 3  1.54 0.074 
Actb Mus musculus actin, beta, cytoplasmic (Actb), mRNA. 1.63 0.074 
Lmod2 leiomodin 2 (cardiac) 0.34 0.074 
Rpp14 ribonuclease P 14 subunit (human) 0.50 0.075 
Foxd3 forkhead box D3 1.52 0.076 
Mb myoglobin 0.49 0.077 
Usp20 ubiquitin specific protease 20 1.51 0.078 
Atp6v0a1 
ATPase, H+ transporting, lysosomal V0 subunit a 
isoform 1  1.51 0.078 
Myo10 myosin X 1.44 0.078 
A330093E20Rik RIKEN cDNA A330093E20 gene 1.42 0.079 
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Pbxip1 
pre-B-cell leukemia transcription factor interacting 
protein 1 1.39 0.079 
Lrrc2 leucine rich repeat containing 2 0.59 0.079 
Rassf5 Ras association (RalGDS/AF-6) domain family 5 1.39 0.081 
Lrp6 low density lipoprotein receptor-related protein 6 1.64 0.082 
Chd7 chromodomain helicase DNA binding protein 7 1.41 0.084 
Myl3 myosin, light polypeptide 3  0.27 0.085 
Vgll4 vestigial like 4 (Drosophila) 1.49 0.085 
Sap30 sin3 associated polypeptide 1.51 0.086 
Il15 interleukin 15 0.61 0.087 
Mrps26 mitochondrial ribosomal protein S26 1.43 0.087 
Tln Mus musculus talin (Tln), mRNA. 1.56 0.087 
Mafb 
v-maf musculoaponeurotic fibrosarcoma oncogene 
family, protein B (avian)  0.54 0.087 
Emp1 epithelial membrane protein 1 1.63 0.087 
1700039I01Rik RIKEN cDNA 1700039I01 gene 1.43 0.087 
2700082O15Rik RIKEN cDNA 2700082O15 gene 0.47 0.087 
Atp1b1 ATPase, Na+/K+ transporting, beta 1 polypeptide  0.51 0.088 
9630033F20Rik RIKEN cDNA 9630033F20 gene 1.68 0.092 
4930438M06Rik 
Mus musculus RIKEN cDNA 4930438M06 gene 
(4930438M06Rik), mRNA. 1.46 0.093 
B430320C24Rik RIKEN cDNA B430320C24 gene 1.83 0.093 
Gatm 
glycine amidinotransferase (L-arginine:glycine 
amidinotransferase) 1.66 0.093 
Amd1 S-adenosylmethionine decarboxylase 1 0.52 0.093 
Atp2a1 
ATPase, Ca++ transporting, cardiac muscle, fast twitch 
1  1.49 0.094 
Adamts4 
a disintegrin-like and metalloprotease (reprolysin type) 
with thrombospondin type 1 motif, 4  1.42 0.094 
Fabp4 fatty acid binding protein 4, adipocyte  0.60 0.096 
Tceal7 transcription elongation factor A (SII)-like 7 1.78 0.097 
Ddc dopa decarboxylase 1.45 0.097 
9530003J23Rik RIKEN cDNA 9530003J23 gene 0.56 0.098 
Spon2 spondin 2, extracellular matrix protein  1.99 0.098 
BC035954 cDNA sequence BC035954 1.39 0.098 
Atp1b1 ATPase, Na+/K+ transporting, beta 1 polypeptide  0.40 0.098 
Zmynd17 zinc finger, MYND domain containing 17  2.81 0.099 
AW822216 expressed sequence AW822216 1.53 0.099 
2310007D09Rik RIKEN cDNA 2310007D09 gene 1.47 0.099 
Myh2 myosin, heavy polypeptide 2, skeletal muscle, adult  0.18 0.099 
6430514B01 hypothetical protein 6430514B01 1.53 0.100 
Gng2 
guanine nucleotide binding protein (G protein), gamma 
2 subunit  1.68 0.100 
Prkag2 
protein kinase, AMP-activated, gamma 2 non-catalytic 
subunit  1.43 0.100 
Pdhb pyruvate dehydrogenase (lipoamide) beta 0.44 0.100 
Fmod fibromodulin 1.75 0.101 
Mapre3 
microtubule-associated protein, RP/EB family, member 
3  1.49 0.102 
Gbp5 guanylate nucleotide binding protein 5 0.59 0.102 
Emid2 EMI domain containing 2 1.41 0.103 
Nfic nuclear factor I/C 1.47 0.104 
Gtl2 
GTL2, imprinted maternally expressed untranslated 
mRNA  2.96 0.105 
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6720458D17Rik RIKEN cDNA 6720458D17 gene 1.81 0.106 
1110033O09Rik RIKEN cDNA 1110033O09 gene 1.40 0.106 
Klk16 kallikrein 16 1.58 0.107 
Pde4b phosphodiesterase 4B, cAMP specific  1.42 0.107 
Slc16a6 
solute carrier family 16 (monocarboxylic acid 
transporters), member 6  1.47 0.107 
Pabpc1 poly A binding protein, cytoplasmic 1  1.41 0.108 
Chrna1 
cholinergic receptor, nicotinic, alpha polypeptide 1 
(muscle)  1.55 0.108 
C130027E04Rik RIKEN cDNA C130027E04 gene 1.42 0.108 
Actn3 actinin alpha 3 1.68 0.109 
0610025O11Rik RIKEN cDNA 0610025O11 gene 1.68 0.109 
Myom3 myomesin family, member 3  0.51 0.110 
9830123M21Rik RIKEN cDNA 9830123M21 gene 1.92 0.112 
Capns1 calpain, small subunit 1  1.46 0.112 
Bin1 bridging integrator 1 1.48 0.113 
Kcnc4 
potassium voltage gated channel, Shaw-related 
subfamily, member 4  1.42 0.113 
Six2 sine oculis-related homeobox 2 homolog (Drosophila) 1.42 0.114 
Lass1 longevity assurance homolog 1 (S. cerevisiae) 1.43 0.116 
2700038N03Rik RIKEN cDNA 2700038N03 gene 1.41 0.117 
Vim Mus musculus vimentin (Vim), mRNA. 1.39 0.118 
A930008A22Rik RIKEN cDNA A930008A22 gene 1.48 0.124 
Myoz2 myozenin 2 0.51 0.125 
Klk13 kallikrein 13 1.47 0.125 
Myh3 
myosin, heavy polypeptide 3, skeletal muscle, 
embryonic  0.59 0.129 
Col16a1 procollagen, type XVI, alpha 1  1.41 0.130 
4832441B07Rik RIKEN cDNA 4832441B07 gene 2.24 0.131 
Alb1 albumin 1 4.07 0.133 
Ddc dopa decarboxylase 1.46 0.133 
Ckap4 cytoskeleton-associated protein 4 1.40 0.133 
Smad7 MAD homolog 7 (Drosophila) 1.55 0.134 
Col1a1 procollagen, type I, alpha 1  1.67 0.134 
Nfix nuclear factor I/X 1.40 0.136 
Gse1 genetic suppressor element 1 1.61 0.137 
Phlda1 pleckstrin homology-like domain, family A, member 1  1.40 0.141 
Rian RNA imprinted and accumulated in nucleus 2.31 0.141 
Gstm1 glutathione S-transferase, mu 1  1.40 0.142 
Fabp1 fatty acid binding protein 1, liver  2.33 0.143 
Ddit4l DNA-damage-inducible transcript 4-like 1.54 0.145 
H19 H19 fetal liver mRNA 1.91 0.149 
Nov nephroblastoma overexpressed gene 1.43 0.151 
Bace1 beta-site APP cleaving enzyme 1 1.56 0.152 
Ktn1 kinectin 1 2.00 0.155 
AI839562 expressed sequence AI839562 1.44 0.158 
Hoxa11 homeo box A11 1.58 0.159 
Myh4 myosin, heavy polypeptide 4, skeletal muscle  1.42 0.160 
Tnfrsf19l 
tumor necrosis factor receptor superfamily, member 19-
like  1.39 0.161 
Csrp3 cysteine and glycine-rich protein 3 0.39 0.163 
1110028C15Rik RIKEN cDNA 1110028C15 gene 0.60 0.163 
Myh1 myosin, heavy polypeptide 1, skeletal muscle, adult  0.56 0.163 
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 mt-Nd1 NADH dehydrogenase 1, mitochondrial  0.54 0.163 
6330500D04Rik RIKEN cDNA 6330500D04 gene 1.48 0.164 
Kazald1 Kazal-type serine protease inhibitor domain 1 1.65 0.164 
Gas1 growth arrest specific 1 1.39 0.165 
Nme7 
Mus musculus non-metastatic cells 7, protein expressed 
in (Nme7), mRNA. 0.42 0.166 
Nr4a2 nuclear receptor subfamily 4, group A, member 2  1.41 0.166 
Lgals3 lectin, galactose binding, soluble 3  1.98 0.167 
Nfil3 nuclear factor, interleukin 3, regulated  1.57 0.167 
Cxcl4 chemokine (C-X-C motif) ligand 4 1.51 0.172 
Tph1 tryptophan hydroxylase 1 1.68 0.173 
Dkk3 dickkopf homolog 3 (Xenopus laevis) 1.78 0.177 
1500015O10Rik RIKEN cDNA 1500015O10 gene 1.55 0.177 
Smyd2 SET and MYND domain containing 2 1.41 0.178 
2310065F04Rik RIKEN cDNA 2310065F04 gene 1.45 0.179 
Pigt phosphatidylinositol glycan, class T  1.45 0.179 
Jarid1d jumonji, AT rich interactive domain 1D (Rbp2 like)  0.60 0.182 
Prg4 
proteoglycan 4 (megakaryocyte stimulating factor, 
articular superficial zone protein)  1.55 0.183 
Mus musculus tropomyosin 3 mRNA, complete cds. 0.50 0.183 
2410003B16Rik RIKEN cDNA 2410003B16 gene 1.53 0.185 
Grem2 
gremlin 2 homolog, cysteine knot superfamily (Xenopus 
laevis)  1.59 0.186 
Mup3 major urinary protein 3 1.76 0.187 
Ambp alpha 1 microglobulin/bikunin 1.53 0.187 
B830012L14Rik RIKEN cDNA B830012L14 gene 2.04 0.189 
Ttr transthyretin 2.14 0.192 
Serpina1a 
serine (or cysteine) proteinase inhibitor, clade A, 
member 1a  1.56 0.193 
1810011O10Rik RIKEN cDNA 1810011O10 gene 0.55 0.194 
C630041L24Rik RIKEN cDNA C630041L24 gene 1.71 0.195 
Mup1 major urinary protein 1 2.09 0.199 
Mup2 major urinary protein 2 2.43 0.204 
Eif2s3y 
eukaryotic translation initiation factor 2, subunit 3, 
structural gene Y-linked  0.36 0.205 
F13a1 coagulation factor XIII, A1 subunit  1.46 0.205 
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